Search

Your search keyword '"A. N. Pardo"' showing total 127 results
Start Over Author "A. N. Pardo"
127 results on '"A. N. Pardo"'

4. Effect of the COVID-19 pandemic on surgery for indeterminate thyroid nodules (THYCOVID): a retrospective, international, multicentre, cross-sectional study

Author

Fabio Medas, Chiara Dobrinja, Ebtesam Abdullah Al-Suhaimi, Julia Altmeier, Said Anajar, Akif Enes Arikan, Irina Azaryan, Lovenish Bains, Giancarlo Basili, Hakan Bolukbasi, Marco Bononi, Farzad Borumandi, Mehmet Buğra Bozan, Gabriela Brenta, Laurent Brunaud, Maximilian Brunner, Antoine Buemi, Gian Luigi Canu, Federico Cappellacci, Sara Burchfield Cartwright, Ignasi Castells Fusté, Beatriz Cavalheiro, Giuseppe Cavallaro, Andres Chala, Shun Yan Bryant Chan, John Chaplin, Mustafa Sajjad Cheema, Costanza Chiapponi, Maria Grazia Chiofalo, Emmanuel Chrysos, Annamaria D'Amore, Michael de Cillia, Carmela De Crea, Nicolò de Manzini, Leandro Luongo de Matos, Loredana De Pasquale, Paolo Del Rio, Marco Stefano Demarchi, Muthuswamy Dhiwakar, Gianluca Donatini, Jose Miguel Dora, Valerio D'Orazi, Viyey Kishore Doulatram Gamgaram, Vitalijus Eismontas, El Hassane Kabiri, Hadj Omar El Malki, Islam Elzahaby, Octavian Enciu, Antoine Eskander, Francesco Feroci, David Figueroa-Bohorquez, Dimitrios Filis, Gorostidi François, Pedro Frías-Fernández, Armando Gamboa-Dominguez, Volkan Genc, Davide Giordano, Antonio Gómez-Pedraza, Giuseppa Graceffa, James Griffin, Sofia Cuco Guerreiro, Karan Gupta, Keshav Kumar Gupta, Angela Gurrado, Jiannis Hajiioannou, Tommi Hakala, Wirsma Arif Harahap, Lindsay Hargitai, Dana Hartl, Andrzej Hellmann, Jiri Hlozek, Van Trung Hoang, Maurizio Iacobone, Nadia Innaro, Orestis Ioannidis, J H Isabelle Jang, Jose Candido Xavier-Junior, Milan Jovanovic, Reto Martin Kaderli, Fahmi Kakamad, Krzysztof Kaliszewski, Martin Karamanliev, Hiroshi Katoh, Andro Košec, Bozidar Kovacevic, Luiz Paulo Kowalski, Robert Králik, Sanjay Kumar Yadav, Adriána Kumorová, Savvas Lampridis, Konstantinos Lasithiotakis, Jean-Christophe Leclere, Eugene Kwong Fei Leong, Melvin Khee-Shing Leow, James Y Lim, Leonardo S Lino-Silva, Shirley Yuk Wah Liu, Núria Perucho Llorach, Celestino Pio Lombardi, Javier López-Gómez, Eleonora Lori, Lourdes Quintanilla-Dieck, Roberta Lucchini, Amin Madani, Dimitrios Manatakis, Ivan Markovic, Gabriele Materazzi, Haggi Mazeh, Giuseppe Mercante, Goswin Yason Meyer-Rochow, Olgica Mihaljevic, Julie A Miller, Michele Minuto, Massimo Monacelli, Francesk Mulita, Barbara Mullineris, José Luis Muñoz-de-Nova, Fábio Muradás Girardi, Saki Nader, Tangjaturonrasme Napadon, Constantinos Nastos, Chiara Offi, Ohad Ronen, Luigi Oragano, Aida Orois, Yongqin Pan, Emmanouil Panagiotidis, Ramakanth Bhargav Panchangam, Theodosios Papavramidis, Pradipta Kumar Parida, Anna Paspala, Òscar Vidal Pérez, Sabrina Petrovic, Marco Raffaelli, Constanza Fernanda Ramacciotti, Tomas Ratia Gimenez, Ángel Rivo Vázquez, Jong-Lyel Roh, Leonardo Rossi, Alvaro Sanabria, Alena Santeerapharp, Arseny Semenov, Sanjeewa Seneviratne, Altinay Serdar, Patrick Sheahan, Sean C Sheppard, Rachel L Slotcavage, Constantin Smaxwil, Soo Young Kim, Salvatore Sorrenti, Eleftherios Spartalis, Chutintorn Sriphrapradang, Mario Testini, Yigit Turk, George Tzikos, Kristina Vabalayte, Kelly Vargas-Osorio, Rafael Sebastián Vázquez Rentería, David Velázquez-Fernández, Sanura Malinda Pallegoda Vithana, Levent Yücel, Erwin Danil Yulian, Petra Zahradnikova, Paul Zarogoulidis, Evgeniia Ziablitskaia, Anna Zolotoukho, Pietro Giorgio Calò, A Abdallah, AL Abentroth, V Acheimastos, M Agunaoun, HM Al Bisher, A Al Ghuzlan, H Alakus, M Alkan, MC Almaraz Almaraz, K Amram, S Anesidis, E Anestiadou, D Angelucci, GL Ansaldo, MI Antonopoulou, M Arciniegas, C Armellin, G Arredondo Saldaña, J Astl, E Athanasakis, S Avenia, H Aydın, B Baba, J Babala, MV Banús, LA Barba-Valadez, SV Barcons, F Battafarano, A Bayat, RMC Bella, F Benariba, S Bernardi, EG Bignami, M Bitenc, S Bitsianis, JDD Bolaños de la Torre, E Bonati, T Bonetti, FA Borges, K Bouchagier, M Boudina, A Bourial, I Breuskin, P Brock, C Bruns, MC Burlacu, T Burton, M Buta, D Buzanakov, C Caliseo, D Callanan, V Calu, JM Cameselle-Teijeiro, DJ Camilo-Junior, S Canberk, V Candalise, F Candanedo-Gonzalez, LJ Carrillo Lizarazo, GB Carvalho, D Casallas, C Casolino, L Castellani, C Castillo Morales, G Chambon, V Chatzipavlidou, R Chernikov, A Chorti, TCM Chow, A Chrisoulidou, E Chrysos, S Conrado-Neto, D Cordova García, A Corigliano, A Crocco, A Cuesta, M Čukman, LS Curto, RA Damilano, R D'Anna, M De, A De Virgilio, D Dellaportas, L Demarquet, A Devresse, G Di Meo, R Diaz Pedrero, D Dimitrov, Z Dmitry, P Domínguez Garijo, O Dulgeroglu, AC Dural, A Eksi, M El Hammoumi, H El Kaoui, G Eleni, A Elliyanti, Ş Ersöz, M Escobar-Jiménez, L Fedorova, L Feeley, E Fernández Rodríguez, F Ferreli, A Filoia, A Fingeret, A Francescato, F Gaino, F Galiandro, JF Gallegos-Hernández, G Garas, F García Lorenzo, JP García-Chávez, M Gaudiello, S Gay, S Gerasimos, M Gerek, R Gervasi, A Giordano, B Gjeloshi, L Gocký, E Golubinskaya, S González Romero, C González-Mínguez, M Goran, A Gosman, M Granados Garcia, E Greco, M Grünbart, R Grützmann, J Guerlain, XG Guirao, D Guzey, A Hajjij, O Hamdy, MS Hameed, LA Hauth, JD Hernández-Acevedo, JF Hernandez-Carrillo, F Hevilla Sánchez, H Hoi, K Hongkwon, R Hu Zhu, E Huang, K Hyeung Kyoo, V Ignjatovic, A Ioannidis, A Iossa, A Işık, D James, L Jung Hoon, H Kara, J Karajovic, D Kartini, D Khambri, I Kholová, M Kisiel, M Knežević, YQ Koh, C Konca, C Kosmidis, G Kotsovolis, LP Kowalski, R Kralik, P Kuczma, BG Kuravi, A Kurnia, V Kyriaki, CM Lai, B Lallemant, AA Lardhi, S Leboulleux, JW Lee, G Lelli, M Leutner, MY Lim, CM Lim, A Llanos, X Lo, T Loderer, MA López-Corrales, M Ludwig, FF Magnabosco, C Maheo, AL Maia, O Makay, P Maksimova, S Mallick, C Mallouk, Z Mamani, S Mandal, M Manyalich Blasi, G Marincola, M Marulanda, M Mavromati, S Mayilvaganan, S Metso, A Micalizzi, A Michalopoulos, K Min-Su, A Miron, AK Mishra, C Misso, C Mittermair, Y Morosán Allo, M Mourad, M Moysidis, F Nabhan, R Nasiri, C Nastos, KY Ngiam, C Nomine-Criqui, AM Ntziovara, JM Nuño Vázquez-Garza, V Nutautiene, K Obtulovičová, L O'Keeffe, NO Okudur, P Ossola, E Ovejero Merino, M Ozdemir, A Pangonis, SS Panigoro, A Panuzi, D Papaconstantinou, N Pardo Matamoros, S Paschou, A Pasculli, K Paterakis, K Peiris, F Pennestrì, M Peppa, P Perdikaris, I Perdikaris, RH Pérez-Soto, S Piana, M Piccoli, D Pietrasanta, G Placentino, I Pliakos, A Polistena, A Pongtippan, G Potard, V Quinn, P Rahul, T Ramos, A Rankin, P Ratnayake, J Reuto-Castillo, A Ridolfo, J Rios-Valencia, P Riss, E Rival, J Rivillas, D Roi, EM Rollo, A Romanchishen, M Romito, J Rotnagl, B Rovcanin, G Russo, M Sabol, S Saki, S Saleh, A Salih, A Saltiki, G Salvador-Camarmo, DK Samal, S Sánchez-Flores, K Sapalidis, D Sarin, H Sarin, N Savkovic, RS Scheffel, AL Scheinpflug, C Scheuba, N Scheyer, M Schmidt, O Senashova, E Serafini, ML Serrano Arévalo, J Shank, ML Shindo, M Shoshkova, M Shvan, M Sičák, TG Silva, O Simó Guerrero, V Skuletic, N Slijepcevic, Z Slovic, P Soares, A Somova, S Soto, S Spiezia, V Stankovic, KJ Stephenson, E Straub, M Summa, S Surani, AA Syed, S Symeonidis, A Taciak, M Tarallo, A Tarle, N Tasis, K Tausanovic, L Tchabashvili, M Thierry, U Tokarczyk, EA Toma, S Topuz, F Torresan, C Uras, C Vaccaro, Á Valdés de Anca, M Valentini, E Varaldo, JG Vartanian, GI Verras, A Vithanage, H Wijayalathge, P Wiriyaamornchai, YLC Wong, P Wongwattana, S Xenaki, S Xie, M Xu, W Yang, S Yilmaz, YF Yılmaz, T Yotsov, MT Zahid, A Zielke, UCL - SSS/IREC/CHEX - Pôle de chirgurgie expérimentale et transplantation, UCL - (SLuc) Service de chirurgie et transplantation abdominale, UCL - SSS/IREC/NEFR - Pôle de Néphrologie, and UCL - (SLuc) Service de néphrologie

Subjects
Endocrinology, Endocrinology, Diabetes and Metabolism, Internal Medicine
Abstract

Since its outbreak in early 2020, the COVID-19 pandemic has diverted resources from non-urgent and elective procedures, leading to diagnosis and treatment delays, with an increased number of neoplasms at advanced stages worldwide. The aims of this study were to quantify the reduction in surgical activity for indeterminate thyroid nodules during the COVID-19 pandemic; and to evaluate whether delays in surgery led to an increased occurrence of aggressive tumours. In this retrospective, international, cross-sectional study, centres were invited to participate in June 22, 2022; each centre joining the study was asked to provide data from medical records on all surgical thyroidectomies consecutively performed from Jan 1, 2019, to Dec 31, 2021. Patients with indeterminate thyroid nodules were divided into three groups according to when they underwent surgery: from Jan 1, 2019, to Feb 29, 2020 (global prepandemic phase), from March 1, 2020, to May 31, 2021 (pandemic escalation phase), and from June 1 to Dec 31, 2021 (pandemic decrease phase). The main outcomes were, for each phase, the number of surgeries for indeterminate thyroid nodules, and in patients with a postoperative diagnosis of thyroid cancers, the occurrence of tumours larger than 10 mm, extrathyroidal extension, lymph node metastases, vascular invasion, distant metastases, and tumours at high risk of structural disease recurrence. Univariate analysis was used to compare the probability of aggressive thyroid features between the first and third study phases. The study was registered on ClinicalTrials.gov, NCT05178186. Data from 157 centres (n=49 countries) on 87 467 patients who underwent surgery for benign and malignant thyroid disease were collected, of whom 22 974 patients (18 052 [78·6%] female patients and 4922 [21·4%] male patients) received surgery for indeterminate thyroid nodules. We observed a significant reduction in surgery for indeterminate thyroid nodules during the pandemic escalation phase (median monthly surgeries per centre, 1·4 [IQR 0·6-3·4]) compared with the prepandemic phase (2·0 [0·9-3·7]; p

Published
2023

5. Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331☆

Author

N. Pardo Aranda, Clarisse Audigier-Valette, Juergen Wolf, David Vicente, Scott J. Antonia, Dimple Pandya, Kazuhiko Nakagawa, David R. Spigel, Solange Peters, Alexander Luft, M. Shi, Ying Cheng, O. Juan-Vidal, Scott N. Gettinger, Martin Reck, J. Fairchild, Parul Doshi, Tudor-Eliade Ciuleanu, Leora Horn, Han Chang, Christine Baudelet, and H. Zhang

Subjects
0301 basic medicine, Oncology, medicine.medical_specialty, Lung Neoplasms, endocrine system diseases, medicine.medical_treatment, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, PD-1, Antineoplastic Combined Chemotherapy Protocols, small-cell lung cancer, Clinical endpoint, Humans, Medicine, Lung cancer, neoplasms, Chemotherapy, business.industry, Hazard ratio, biomarkers, Hematology, medicine.disease, Small Cell Lung Carcinoma, Progression-Free Survival, humanities, Confidence interval, respiratory tract diseases, PD-1, biomarkers, immunotherapy, small-cell lung cancer, Nivolumab, 030104 developmental biology, 030220 oncology & carcinogenesis, Topotecan, immunotherapy, Neoplasm Recurrence, Local, business, Amrubicin, medicine.drug
Abstract

Patients with relapsed small-cell lung cancer (SCLC) have few treatment options and dismal survival. Phase I/II data show activity of nivolumab in previously treated SCLC.CheckMate 331 is a randomized, open-label, phase III trial of nivolumab versus standard chemotherapy in relapsed SCLC. Patients with relapse after first-line, platinum-based chemotherapy were randomized 1 : 1 to nivolumab 240 mg every 2 weeks or chemotherapy (topotecan or amrubicin) until progression or unacceptable toxicity. Primary endpoint was overall survival (OS).Overall, 284 patients were randomized to nivolumab and 285 to chemotherapy. Minimum follow-up was 15.8 months. No significant improvement in OS was seen with nivolumab versus chemotherapy [median OS, 7.5 versus 8.4 months; hazard ratio (HR), 0.86; 95% confidence interval (CI), 0.72-1.04; P = 0.11]. A survival benefit with nivolumab was suggested in patients with baseline lactate dehydrogenase ≤ upper limit of normal and in those without baseline liver metastases. OS (nivolumab versus chemotherapy) was similar in patients with programmed death-ligand 1 combined positive score ≥1% versus1%. Median progression-free survival was 1.4 versus 3.8 months (HR, 1.41; 95% CI, 1.18-1.69). Objective response rate was 13.7% versus 16.5% (odds ratio, 0.80; 95% CI, 0.50-1.27); median duration of response was 8.3 versus 4.5 months. Rates of grade 3 or 4 treatment-related adverse events were 13.8% versus 73.2%.Nivolumab did not improve survival versus chemotherapy in relapsed SCLC. No new safety signals were seen. In exploratory analyses, select baseline characteristics were associated with improved OS for nivolumab.

Published
2021
Full Text
View/download PDF

6. Methodology for Power Quality Measurement Synchronization Based on GPS Pulse-Per-Second Algorithm

Author

Daniel Morinigo-Sotelo, Oscar N. Pardo-Zamora, Rene de Jesus Romero-Troncoso, Roque Alfredo Osornio-Rios, and Jesus Roberto Millan-Almaraz

Subjects
Computer science, business.industry, 020208 electrical & electronic engineering, Real-time computing, 02 engineering and technology, Signal, Atomic clock, Synchronization, Data logger, 0202 electrical engineering, electronic engineering, information engineering, Global Positioning System, Satellite, Stage (hydrology), Electrical and Electronic Engineering, business, Instrumentation
Abstract

Power quality disturbances (PQD) are generated by nonlinear loads and they propagate through the electrical grid to other sensitive devices causing malfunction. To study the propagation of PQD, it is important to perform synchronized and simultaneous measurements at multiple locations in the electrical network. This article proposes a methodology to synchronize measurements of electrical variables at multiple locations in the electrical grid based on the synchronization of the internal time reference of several data loggers with the pulse per second (PPS) reference provided by a global positioning system (GPS) receiver module. As the PPS signal is synchronized to the atomic clocks of the satellites in the GPS, a precise time reference in multiple sites can be obtained simultaneously. The proposed methodology has been tested in two stages. The first stage is a validation experiment that compares the number of samples obtained between three GPS synchronized data loggers and two data loggers with internal synchronization only. The PPS signal has been interrupted in one GPS synchronized data logger to simulate a signal loss and test the resynchronization capability of the methodology. A very low synchronization error has been obtained for the GPS synchronized data loggers, whereas the data loggers with the internal synchronization show greater synchronization errors. The second stage consists in experimental case of study measuring electrical variables in multiple locations of a real electrical grid where the propagation of multiple disturbances is tracked with the GPS synchronized data loggers.

Published
2021
Full Text
View/download PDF

9. Content Hub como proceso pedag?gico para los docentes del Colegio Adventista de Villavicencio

Author

Calder?n Pardo, H?ctor Mauricio and Ruiz Perdomo, Patricia [tutor]

Subjects
Content Hub, TIC, Competencia digital, Trabajo de grado-Maestr?a, Pedag?gico, Docente
Abstract

La propuesta Content Hub como proceso pedag?gico para los docentes del Colegio Adventista de Villavicencio, tuvo como prop?sito general fortalecer el proceso pedag?gico en los docentes del Colegio Adventista sede Villavicencio, mediante la implementaci?n y desarrollo del Content Hub. La propuesta desarroll? una metodolog?a con enfoque cualitativo de corte descriptivo y un dise?o metodol?gico de estudio de caso de tipo transversal no experimental. La poblaci?n objeto de estudio correspondi? a los 20 docentes del Colegio Adventista de Villavicencio. Como instrumento se dise?? un cuestionario tipo Likert para conocer el nivel de competencia digital (competencia tecnol?gica, pedag?gica, comunicativa de gesti?n e investigativa) de los docentes, el cual se aplic? antes de la propuesta y posterior a ella. Los resultados permitieron encontrar que los docentes en la etapa inicial presentan un nivel de competencia digital b?sico en el cual exploran algunas herramientas digitales, pero no han logrado darle el uso adecuado al integrarlo al aula de clase. Con el dise?o de la propuesta de Content Hub se almacenaron recursos en un espacio virtual permitiendo que el docente pueda acondicionar estas plantillas a las necesidades del aula, adicional a ello el autor de la propuesta realiz? una socializaci?n con ellos de manera presencial en la cual present? el contenido de la estrategia; posterior a ello, se divulg? nuevamente el instrumento aplicado con el fin de contrastar los resultados obtenidos en la etapa inicial, este proceso arroj? que los docentes mostraron mayor conocimiento, dominio e inter?s en incursionar en el uso de estas herramientas en los procesos diarios de clase. En conclusi?n el proceso permiti? conceptualizar que existen necesidades en los docentes para afrontar el reto de la articulaci?n de las TIC en el aula de clase, lo cual demuestra la viabilidad y pertinencia de la propuesta presentada como espacio enriquecedor y formativo para los docentes. The content hub proposal as a pedagogical process for the teachers at the Adventist College of Villavicencio, which had as its general purpose to strengthen the pedagogical process in the teachers of the Adventist School headquarters Villavicencio, through the implementation and development of the Content Hub. The proposal developed a methodology with a qualitative descriptive approach and a methodological design of non-experimental cross-sectional type case study. The population under study corresponded to the 20 teachers of the Adventist College of Villavicencio. As an instrument, a Likert questionnaire was designed to know the level of digital competence (technological, pedagogical, communicative management and research competence) of the teachers, which was applied before the proposal and after it. The results allowed to find that teachers in the initial stage present a level of basic digital competence in which they explore some digital tools but have not managed to give it the proper use when integrating it into the classroom. With the design of the Content Hub proposal, resources were stored in a virtual space allowing the teacher to condition these templates to the needs of the classroom, in addition to this the author of the proposal made a socialization with them in person in which he introduced the strategy; after that, the instrument applied was disclosed again in order to contrast the results obtained in the initial stage, this process showed that the teachers showed greater knowledge, mastery and interest in venturing these tools in the daily processes of class. In conclusion, the process allowed to conceptualize that there are needs in teachers to face the challenge of the articulation of ICT in the classroom, which demonstrates the viability and relevance of the proposal presented as an enriching and formative space for teachers. Maestr?a Mag?ster en Did?cticas de las Tics

Published
2021

10. Efficacy of chemotherapy for malignant pleural mesothelioma according to histology in a real-world cohort

Author

Susana Cedres, Alex Martinez-Marti, Juan-David Assaf, Caterina Carbonell, D. Marmolejo, Joan Frigola, Rodrigo Dienstmann, N. Pardo, A. Pedrola, Enriqueta Felip, P. Iranzo, Alejandra Rezqallah, Ramon Amat, A. Callejo, Alejandro Navarro, Institut Català de la Salut, [Cedres S, Assaf JD, Iranzo P, Callejo A, Pardo N, Navarro A, Martinez-Marti A, Marmolejo D, Rezqallah A] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Carbonell C, Frigola J, Amat R] Thoracic Cancers Translational Genomics Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Pedrola A, Dienstmann R] Oncology Data Science (ODysSey Group), Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Felip E] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Thoracic Cancers Translational Genomics Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
Oncology, Mesothelioma, Male, Cancer therapy, medicine.medical_treatment, Other subheadings::Other subheadings::/drug therapy [Other subheadings], chemistry.chemical_compound, Pleura - Malalties - Tractament, neoplasias::neoplasias por tipo histológico::neoplasias glandulares y epiteliales::adenoma::mesotelioma [ENFERMEDADES], Aged, 80 and over, education.field_of_study, Multidisciplinary, Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Pleural Neoplasms [DISEASES], Middle Aged, Treatment Outcome, Cohort, Medicine, Pleura, Female, medicine.drug, Neoplasms::Neoplasms by Histologic Type::Neoplasms, Glandular and Epithelial::Adenoma::Mesothelioma [DISEASES], medicine.medical_specialty, Science, Pleural Neoplasms, Population, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], Antineoplastic Agents, neoplasias::neoplasias por localización::neoplasias torácicas::neoplasias del tracto respiratorio::neoplasias pleurales [ENFERMEDADES], Article, Internal medicine, medicine, Humans, Progression-free survival, education, Aged, Retrospective Studies, Cisplatin, Chemotherapy, Mesotelioma - Tractament, Proportional hazards model, business.industry, Mesothelioma, Malignant, diagnóstico::pronóstico::resultado del tratamiento [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Histology, Diagnosis::Prognosis::Treatment Outcome [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Survival Analysis, Carboplatin, chemistry, Avaluació de resultats (Assistència sanitària), business
Abstract

Cancer therapy; Mesothelioma Terapia del cáncer; Mesotelioma Teràpia del càncer; Mesotelioma CheckMate 743 trial demonstrated survival benefit of immunotherapy in first line in MPM with some differences in the efficacy of chemotherapy according to histology. The objective of this study is to characterize the impact of chemotherapy according to histology in patients diagnosed with MPM at our institution. Clinical records of all MPM patients diagnosed at Vall d’Hebron University Hospital between November 2002 and April 2020 were reviewed. Associations between clinical variables and outcomes were assessed with Cox regression models. Survival data were calculated by the Kaplan–Meier method. 189 patients were included with 76% of tumors classified as epithelioid subtype. First line chemotherapy was offered to 85% of patients. Median survival in overall population was 21.3 months (95% CI 17.2–24.3). We found that patients with epithelioid tumors had better overall survival (OS) and progression free survival (PFS). Median OS of epithelioid patients treated with first line chemotherapy was 26.7 months versus 15.0 months in non-epithelioid patients (HR 2.25 CI 95% 1.4–3.4; p

Published
2021

11. Genetic evolution to tyrosine kinase inhibitory therapy in patients with EGFR-mutated non-small-cell lung cancer

Author

Alejandro Navarro, Francesco M. Mancuso, Irene Sansano, Susana Cedres, Ana Vivancos, Judit Matito, Ginevra Caratu, Paolo Nuciforo, Miriam Sansó, P. Iranzo, J.M. Miquel, A. Callejo, N. Pardo, Enriqueta Felip, Nely Diaz-Mejia, and Alex Martinez-Marti

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Lung Neoplasms, Tumour heterogeneity, Article, Metastasis, Lesion, Evolution, Molecular, Text mining, Internal medicine, Carcinoma, Non-Small-Cell Lung, Biopsy, medicine, Humans, Epidermal growth factor receptor, Lung cancer, Protein Kinase Inhibitors, medicine.diagnostic_test, biology, business.industry, High-Throughput Nucleotide Sequencing, medicine.disease, respiratory tract diseases, ErbB Receptors, biology.protein, medicine.symptom, business, Tyrosine kinase
Abstract

Background Tumour heterogeneity impacts the efficacy of metastatic cancer treatment even if actionable mutations are identified. Clinicians need to understand if assessing one lesion provides reliable information to drive a therapeutic decision in non-small-cell lung cancer (NSCLC) patients. Methods We analysed inter-tumour heterogeneity from five autopsied individuals with NSCLC-harbouring mutations in the epidermal growth factor receptor (EGFR), treated with EGFR tyrosine kinase inhibitors (TKIs). Through a comprehensive next-generation sequencing (NGS) oncopanel, and an EGFR panel for digital droplet PCR (ddPCR), we compared metastases within individuals, longitudinal biopsies from the same lesions and, whenever possible, the primary naive tumour. Results Analysis of 22 necropsies from five patients revealed homogeneity in pathogenic mutations and TKI-resistance mechanisms within each patient in four of them. In-depth analysis by whole-exome sequencing from patient 1 confirmed homogeneity in clonal mutations, but heterogeneity in passenger subclonal alterations. Different resistance mechanisms were detected depending on the patient and line of treatment. Three patients treated with a c-MET inhibitor in combination with TKI lost MET amplification upon progression. Conclusion At a given point and under selective TKI pressure, a single metastasis biopsy in disseminated tumours from EGFR-mutated NSCLC patients could provide a reasonable assessment of actionable alterations useful for therapeutic decisions.

Published
2021

12. Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung Cancer

Author

Anna Kostenko, Enriqueta Felip, Bianca van Veggel, Ruth Seggewiss-Bernhardt, Jürgen Wolf, Stefan Haneder, Reinhard Büttner, Vanessa Rüsseler, Eva Geissinger, Johannes Brägelmann, Andreas Rosenwald, Jan Stratmann, Michael Puesken, Matthias Scheffler, Michaela Angelika Ihle, Rieke Fischer, Egbert F. Smit, Martin L. Sos, N. Pardo, Frank Griesinger, Sabine Merkelbach-Bruse, Sebastian Michels, Andreas H. Scheel, Susanne Steinhauser, Hans-Georg Kopp, Lucia Nogova, Ernst Rodermann, Barbara Deschler-Baier, Alex Martinez-Marti, Jana Fassunke, Martin Hellmich, Thorsten Persigehl, Martin Sebastian, Adrianus J. de Langen, Werner Spengler, Carina Heydt, Kim Monkhorst, Walburga Engel-Riedel, Dennis Plenker, Joachim Diebold, Lukas C. Heukamp, Bart Vrugt, and Oliver Gautschi

Subjects
0301 basic medicine, Cancer Research, Genomic profiling, biology, business.industry, medicine.disease, Third generation, respiratory tract diseases, 03 medical and health sciences, Egfr tki, 030104 developmental biology, 0302 clinical medicine, Acquired resistance, Oncology, 030220 oncology & carcinogenesis, Cancer research, biology.protein, Original Report, Medicine, Epidermal growth factor receptor, business, Lung cancer, Tyrosine kinase, Epidermal growth factor receptor tyrosine kinase
Abstract

PURPOSE Third-generation epidermal growth factor receptor ( EGFR) tyrosine kinase inhibitors (TKIs) are effective in acquired resistance (AR) to early-generation EGFR TKIs in EGFR-mutant lung cancer. However, efficacy is marked by interindividual heterogeneity. We present the molecular profiles of pretreatment and post-treatment samples from patients treated with third-generation EGFR TKIs and their impact on treatment outcomes. METHODS Using the databases of two lung cancer networks and two lung cancer centers, we molecularly characterized 124 patients with EGFR p.T790M-positive AR to early-generation EGFR TKIs. In 56 patients, correlative analyses of third-generation EGFR TKI treatment outcomes and molecular characteristics were feasible. In addition, matched post-treatment biopsy samples were collected for 29 patients with progression to third-generation EGFR TKIs. RESULTS Co-occurring genetic aberrations were found in 74.4% of EGFR p.T790-positive samples (n = 124). Mutations in TP53 were the most frequent aberrations detected (44.5%; n = 53) and had no significant impact on third-generation EGFR TKI treatment. Mesenchymal-epithelial transition factor ( MET) amplifications were found in 5% of samples (n = 6) and reduced efficacy of third-generation EGFR TKIs significantly (eg, median progression-free survival, 1.0 months; 95% CI, 0.37 to 1.72 v 8.2 months; 95% CI, 1.69 to 14.77 months; P ≤ .001). Genetic changes in the 29 samples with AR to third-generation EGFR TKIs were found in EGFR (eg, p.T790M loss, acquisition of p.C797S or p.G724S) or in other genes (eg, MET amplification, KRAS mutations). CONCLUSION Additional genetic aberrations are frequent in EGFR-mutant lung cancer and may mediate innate and AR to third-generation EGFR TKIs. MET amplification was strongly associated with primary treatment failure and was a common mechanism of AR to third-generation EGFR TKIs. Thus, combining EGFR inhibitors with TKIs targeting common mechanisms of resistance may delay AR.

Published
2019
Full Text
View/download PDF

13. Implementación del algoritmo VNS-DEEPSO para el despacho de energía en redes distribuidas inteligentes

Author

Pedro Julián García-Guarín, Camilo Andres Cortes-Guerrero, Maria Alejandra Guzma´n Pardo, Julián Cantor, and Sergio Antonio Rivera Rascón

Subjects
Optimization, Renewable energy, Electric vehicles, Computer science, Welfare economics, Energía renovable, Intelligent network, Smart grid, Energy dispatch, Optimización, Algoritmos heurísticos, Metaheuristic algorithms, Vehículos eléctricos, Heuristic algorithms, Operational costs
Abstract

Introducción− Las redes eléctricas tradicionales están migrando a nuevas configuraciones de redes inteligentes, que traen retos operacionales y de planeación. Con miras a avanzar en estos retos se propone resolver un problema de optimización usando programación en elementos de redes distribuidas inteligentes. Objetivo− El problema de optimización consiste en adminis-trar el despacho energético de una red inteligente para opti-mizar los recursos disponibles, considerando la incertidum-bre de energías renovables, viajes planeados de vehículos eléctricos, el pronóstico de carga y los precios del mercado. Metodología− Se propuso utilizar un ensamble entre dos métodos heurísticos. El algoritmo VNS (Variable Neigh-borhood Search) y el DEEPSO (Differential Evolutionary Particle Swarm).Resultados− El algoritmo VNS-DEEPSO fue evaluado en una competencia de “Smart Grids” con otros algoritmos con un valor de 18.21, siendo 7 % mejor que el segundo algoritmo clasificado en la competencia.Conclusiones− El algoritmo VNS-DEEPSO fue ganador entre 9 algoritmos metaheurísticos que solucionaron el prob-lema, este problema tenía un mayor incremento de dificultad debida a la incertidumbre generada por factores ambien-tales, pronóstico de carga, viajes en vehículos eléctricos y el mercado de precios. Acorde a los resultados, el algoritmo VNS-DEEPSO demostró ser el más eficiente en minimizar los costos operacionales y maximizar los ingresos de la red inteligente. Introduction− Traditional electric networks are mi-grating to new configurations of intelligent networks, which bring operational and planning challenges. In order to advance in these challenges, an optimization problem is proposed to solve in the programming of intelligent network elements.Objective− The optimization problem consists of man-aging the energy dispatch of an intelligent network to optimize the available resources, considering the uncer-tainty of renewable energies, planned trips of electric vehicles, cargo forecast and market prices.Methodology− It was proposed to use an assembly between two heuristic methods. The VNS algorithm (Variable Neighborhood Search) and the DEEPSO (Dif-ferential Evolutionary Particle Swarm).Results− The value obtained by the VNS-DEEPSO algorithm was 18.21, being 7 % better than the second algorithm classified in the competition. Conclusions− The VNS-DEEPSO algorithm was the winner among 9 metaheuristic algorithms that solved the problem. This problem has a greater increase in difficulty due to the uncertainty generated by weather conditions, load forecast, planned EV ́s trips, and mar-ket prices. According to the results, the VNS-DEEPSO algorithm proved to be the most efficient in minimizing operational costs and maximizing the revenues of the intelligent network.

Published
2019
Full Text
View/download PDF

16. Interrelations between Patients’ Clinicopathological Characteristics and Their Association with Response to Immunotherapy in a Real-World Cohort of NSCLC Patients

Author

Joan Frigola, Caterina Carbonell, Enriqueta Felip, Alejandro Navarro, P. Iranzo, Alex Martinez-Marti, A. Callejo, Nely Diaz, D. Marmolejo, Ramon Amat, Susana Cedres, J.D. Assaf, N. Pardo, Institut Català de la Salut, [Callejo A, Iranzo P, Diaz N, Assaf JD, Cedrés S, Martinez-Marti A, Navarro A, Pardo N] Clinical Research Department, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Frigola J, Carbonell C, Amat R] Thoracic Cancers Translational Genomics Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Marmolejo D] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Felip E] Clinical Research Department, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Thoracic Cancers Translational Genomics Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
0301 basic medicine, Oncology, Cancer Research, medicine.medical_specialty, Multivariate analysis, LDH, medicine.medical_treatment, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], ECOG Performance Status, Other subheadings::Other subheadings::/drug therapy [Other subheadings], NSCLC, Article, immune checkpoint inhibitors, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Medicine, Other subheadings::/therapeutic use [Other subheadings], Adverse effect, Survival analysis, RC254-282, Medicaments antineoplàstics - Ús terapèutic - Eficàcia, Otros calificadores::/uso terapéutico [Otros calificadores], business.industry, Hazard ratio, acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos [COMPUESTOS QUÍMICOS Y DROGAS], Neoplasms. Tumors. Oncology. Including cancer and carcinogens, biomarkers, Retrospective cohort study, Immunotherapy, Neoplasms::Neoplasms by Site::Thoracic Neoplasms::Respiratory Tract Neoplasms::Lung Neoplasms::Bronchial Neoplasms::Carcinoma, Bronchogenic::Carcinoma, Non-Small-Cell Lung [DISEASES], neoplasias::neoplasias por localización::neoplasias torácicas::neoplasias del tracto respiratorio::neoplasias pulmonares::neoplasias de los bronquios::carcinoma broncogénico::carcinoma de pulmón de células no pequeñas [ENFERMEDADES], immune related adverse events, 030104 developmental biology, 030220 oncology & carcinogenesis, Cohort, immunotherapy, Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents [CHEMICALS AND DRUGS], business, Pulmons - Càncer - Tractament
Abstract

Immune checkpoint inhibitors (ICIs) have transformed non-small cell lung cancer (NSCLC) treatment. Unfortunately, only some patients benefit from these therapies. Thus, certain clinicopathological characteristics of the patients have been proposed as biomarkers of ICIs response. We assembled a retrospective cohort of 262 NSCLC patients treated with ICIs, compiled relevant clinicopathological characteristics, and studied their associations with treatment outcome using Cox proportional-hazards survival models. Additionally, we investigated the interrelations between clinicopathological features and devised a method to create a compendium associated with ICIs response by selecting those that provide non-redundant information. In multivariate analyses, ECOG performance status (hazard ratio (HR) 1.37 (95% CI 1.11 to 1.68), p &lt, 0.005), LDH (HR 1.24 (95% CI 1.03 to 1.48), p = 0.02)) and PD-L1 negativity were associated with decreased PFS (HR 1.92 (95% CI 1.03 to 3.58), p &lt, 0.04), whereas presentation of immune-related adverse events (irAEs) (HR 0.35 (95% CI 0.22 to 0.55, p &lt, 0.005) or females (HR 0.52 (95% CI 0.33 to 0.80, p &lt, 0.005) had longer progression-free survival. Additionally, numerous clinicopathological indicators were found to be interrelated. Thus, we searched for features that provide non-redundant information, and found the combination of LDH levels, irAEs, and gender to have a better association with ICIs treatment response (cross-validated c-index = 0.66). We concluded that several clinicopathological features showed prognostic value in our real-world cohort. However, some are interrelated, and compendiums of features should therefore consider these interactions. Joint assessment of LDH, irAEs, and gender may be a good prognostic compendium.

Published
2021
Full Text
View/download PDF

17. Power Quality Disturbance Tracking Based on a Proprietary FPGA Sensor with GPS Synchronization

Author

Daniel Morinigo-Sotelo, Jesus Roberto Millan-Almaraz, Oscar N. Pardo-Zamora, Roque Alfredo Osornio-Rios, Rene de Jesus Romero-Troncoso, and Jose A. Antonino-Daviu

Subjects
Sistemas de posicionamiento global, field-programmable gate array, Computer science, 020209 energy, Fast Fourier transform, Real-time computing, Wavelet Analysis, Swarm intelligence, 02 engineering and technology, TP1-1185, Biochemistry, Article, Analytical Chemistry, genetic algorithms, Synchronization (alternating current), Data logger, Electronic circuits, global positioning system, propagation, 0202 electrical engineering, electronic engineering, information engineering, Energía eléctrica - Calidad - Control, Electrical and Electronic Engineering, power quality disturbance, Instrumentation, Fourier Analysis, particle swarm optimization, business.industry, Chemical technology, 020208 electrical & electronic engineering, Wavelet transform, Particle swarm optimization, Field programmable gate arrays, Grid, Instalaciones industriales, Atomic and Molecular Physics, and Optics, Electric power systems - Quality control, Harmonic, Global Positioning System, INGENIERIA ELECTRICA, industrial facilities, Circuitos electrónicos, Algoritmos genéticos, business, 3306 Ingeniería y Tecnología Eléctricas, Algorithms
Abstract

Producción Científica, The study of power quality (PQ) has gained relevance over the years due to the increase in non-linear loads connected to the grid. Therefore, it is important to study the propagation of power quality disturbances (PQDs) to determine the propagation points in the grid, and their source of generation. Some papers in the state of the art perform the analysis of punctual measurements of a limited number of PQDs, some of them using high-cost commercial equipment. The proposed method is based upon a developed proprietary system, composed of a data logger FPGA with GPS, that allows the performance of synchronized measurements merged with the full parameterized PQD model, allowing the detection and tracking of disturbances propagating through the grid using wavelet transform (WT), fast Fourier transform (FFT), Hilbert–Huang transform (HHT), genetic algorithms (GAs), and particle swarm optimization (PSO). Measurements have been performed in an industrial installation, detecting the propagation of three PQDs: impulsive transients propagated at two locations in the grid, voltage fluctuation, and harmonic content propagated to all the locations. The results obtained show that the low-cost system and the developed methodology allow the detection of several PQDs, and track their propagation within a grid with 100% accuracy., Consejo Nacional de Ciencia y Tecnología (CONACYT) - (grant 486847)

Published
2021
Full Text
View/download PDF

18. Craneoplastia en pacientes con craniectomia descompresiva por un traumatismo craneoencefalico grave

Author

Lacerda Gallardo, Angel J., Martín Pardo, Julio C., Martín Chaviano, Daiyan, Tacas Gil, Norka, Quintana Zaez, Johanna, and Mirabal García, Yaíma

Subjects
Health
Abstract

Introducción: La reconstrucción del defecto óseo de la bóveda craneal en pacientes craniectomizados sobrevivientes de un traumatismo craneoencefálico grave se ha convertido en un procedimiento frecuente en el funcionamiento neuroquirúrgico de nuestro servicio. Objetivos: Relacionar el tiempo promedio de realización de la craneoplastia con la aparición de manifestaciones clínicas y complicaciones. Métodos: Se realizó un estudio correlacional prospectivo con un grupo de pacientes que sobrevivieron luego de un traumatismo craneoencefálico grave y que mostraron defectos óseos de la bóveda craneal como consecuencia de una craniectomía descompresiva uni o bilateral, los que fueron sometidos a procedimientos reconstructivos para corregir la deformidad, en el período comprendido entre enero de 2003 y diciembre de 2011, en el servicio de neurocirugía del hospital universitario 'Roberto Rodríguez', de la ciudad de Morón, Ciego de Ávila, Cuba. Resultados: Se evaluaron 33 casos (47,14%), 23 (69,7%) del sexo masculino y 10 (30,3%) del femenino. Se realizaron 29 (87,88%) procedimientos fronto-temporo- parietooccipitales (FTPO) unilaterales, dos FTPO bilaterales (6,06%) y dos (6,06%) bifrontales. Entre uno y tres meses fueron reconstruidos seis cráneos (18,18%) y con más de tres meses de evolución 27 (81,82%), 22 de ellos (66,67%) entre cuatro y seis meses y con más de seis meses de evolución se operaron cinco casos (15,15%). Cinco casos mostraron complicaciones relacionadas con la craneoplastia (15,15%) y seis (18,18%) tenían diagnóstico de síndrome post craniectomía en el momento de la craneoplastia, todos con más de tres meses de evolución. Conclusiones: Con el presente estudio no fue posible demostrar la existencia de correlación entre el tiempo de realización de la craneoplastia en pacientes craniectomizados con los resultados. Palabras clave: Craniectomía descompresiva, craneoplastia, traumatismo craneoencefálico grave. Introduction: Craneoplasty in patients with decompressive craniectomy after severe head trauma is one of the most common surgical procedures in our hospital. Objetives: The aim of the investigation was to know the timing of craneoplasty and its relation with the complications. Method: We have conducted a prospectively study from January 2003 to december 2011 with 33 cranioplasty procedures in patients who previously underwent decompressive craniectomy after severe head trauma. Patients were stratified into two groups according to the time from DC to cranioplasty (1-3 months, and more than 3 months). Results: Overall craneoplasty was performed between 1-3 months in 18.18% (early cranioplasty), and more than 3 months in 81,82% (Late cranioplasty). Five patients (15.15 %) shows complications after cranioplasty, 2 (6.06%) with early and 3 (9.09%) with late cranioplasty. Conclusions: In this study we can't correlate the timing of cranioplasty after decomresive craniectomy with complications. Key words: Decompressive craniectomy, cranioplasty, severe head trauma., Introducción El traumatismo craneoencefálico grave (TCEG) es una de las principales causas de morbilidad y mortalidad en el mundo, alrededor del 50% de aquellos que sufren un accidente, presentarán un [...]

Published
2013

19. 1733P Analysis of chemotherapy (Ct) efficacy according to histology in malignant pleural mesothelioma (MPM) patients (p)

Author

Cedres, S., primary, Assaf, J.D., additional, Gomez, P. Iranzo, additional, Perez, A. Callejo, additional, Aranda, N. Pardo, additional, Navarro, A., additional, Martinez-Marti, A., additional, Castaneda, D.H. Marmolejo, additional, Aron, M.A. Rezqallah, additional, Pedrola, A., additional, Gonzalo, J., additional, Frigola, J., additional, Carbonell, C., additional, Amat, R., additional, Dienstmann, R., additional, and Felip, E., additional

Published
2021
Full Text
View/download PDF

20. 2193P Real-world evidence of the impact of immunotherapy (IT) on overall survival (OS) of patients (p) with malignant pleural mesothelioma (MPM) adjusted for tumor histology

Author

Perez, S.M. Cedres, Valdivia, A.A., Pastrana, J.D. Assaf, Gomez, P. Iranzo, Perez, A. Callejo, Aranda, N. Pardo, Mendivil, A.F. Navarro, Martinez-Marti, A., Priano, I., Hermida, J.M. Ucha, Garcia-Galea, E., Gonzalo, J., Caro, R., Carbonell, C., Amat, R., Dienstmann, R., and Felip, E.

Published
2023
Full Text
View/download PDF

21. 1733P Analysis of chemotherapy (Ct) efficacy according to histology in malignant pleural mesothelioma (MPM) patients (p)

Author

M.A. Rezqallah Aron, D.H. Marmolejo Castaneda, Caterina Carbonell, A. Pedrola, Jaime Frigola, Susana Cedres, Rodrigo Dienstmann, Ramon Amat, J. Gonzalo, N. Pardo Aranda, Atilio Navarro, A. Callejo Perez, P. Iranzo Gomez, Enriqueta Felip, Alex Martinez-Marti, and J.D. Assaf

Subjects
medicine.medical_specialty, Chemotherapy, Oncology, Pleural mesothelioma, business.industry, medicine.medical_treatment, medicine, Histology, Hematology, Radiology, business
Published
2021
Full Text
View/download PDF

22. Activity of HSP90 Inhibiton in a Metastatic Lung Cancer Patient With a Germline BRCA1 Mutation

Author

Francesco M. Mancuso, Judith Balmaña, Alex Martinez-Marti, Ana Maria Martinez de Castro, Paolo Nuciforo, Irene Sansano, Cristina Cruz, Ana Vivancos, Jorge Zeron-Medina, Jordin Remon, Violeta Serra, Susana Cedres, N. Pardo, Alba Llop-Guevara, Enriqueta Felip, Alejandro Navarro, and J.M. Miquel

Subjects
Adult, 0301 basic medicine, Cancer Research, Lung Neoplasms, medicine.medical_treatment, Population, Breast Neoplasms, Brief Communication, Deoxycytidine, Maintenance Chemotherapy, 03 medical and health sciences, 0302 clinical medicine, Germline mutation, Breast cancer, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Humans, Medicine, HSP90 Heat-Shock Proteins, education, Germ-Line Mutation, Cisplatin, Chemotherapy, education.field_of_study, BRCA1 Protein, business.industry, Carcinoma, Ductal, Breast, Isoxazoles, Resorcinols, medicine.disease, Gemcitabine, Chemotherapy regimen, Treatment Outcome, 030104 developmental biology, Oncology, 030220 oncology & carcinogenesis, Cancer research, Female, business, medicine.drug
Abstract

Heat shock proteins (HSPs) are molecular chaperones that maintain proteins in their correct conformation to ensure stability and protect carcinoma cells from apoptosis. HSP90 inhibitors (HSP90i) block multiple targets simultaneously, and despite responses in a selected population, no HSP90i have yet been approved. We present a patient with a lung tumor with an exceptional response to cisplatin/gemcitabine in combination with HSP90i, which nowadays continues with HSP90i maintenance after three years. Whole-exome sequencing of the lung tumor unveiled a BRCA1/2 deficiency mutational signature, and mutation analysis confirmed a germline BRCA1 mutation. The striking efficacy of HSP90i plus chemotherapy vs chemotherapy alone was reproduced in a patient-derived xenograft (PDX) model from a breast cancer patient with a BRCA1 mutation (mean tumor volume [SD], No. of tumors: vehicle 8.38 [7.07] mm3, n = 3; HSP90i 4.18 [1.93] mm3, n = 5; cisplatin plus gemcitabine 3.31 [1.95] mm3, n = 5; cisplatin plus gemcitabine plus HSP90i 0.065 [0.076] mm3, n = 6). This case and the PDX demonstrate the efficacy for therapeutic inhibition of HSP90 in a BRCA-mutated patient, opening a new potential avenue for better identifying patients who might benefit most from HSP90i.

Published
2018
Full Text
View/download PDF

23. MA04.07 Clinical Characteristics and Outcomes in Patients With Malignant Pleural Mesothelioma (MPM) with COVID-19 Infection

Author

Ramon Amat, Alex Martinez-Marti, P. Iranzo, Rodrigo Dienstmann, Joan Frigola, Enriqueta Felip, D. Marmolejo, J. Gonzalo, Cristina Viaplana, N. Pardo, Caterina Carbonell, J.D. Assaf, Susana Cedres, Atilio Navarro, and A. Rezqallah

Subjects
Pulmonary and Respiratory Medicine, Oncology, 2019-20 coronavirus outbreak, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), business.industry, Pleural mesothelioma, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Ma04 Current Status and Future Prospects of Pleural Mesothelioma and Thymoma Wednesday, September 08, 2021 - 10:45-11:45, Internal medicine, Medicine, In patient, business
Published
2021

24. P24.06 Real World use of Cisplatin and Carboplatin Based Therapy in Patients with Malignant Pleural Mesothelioma (MPM)

Author

A. Valdivia, J. Gonzalo, P. Iranzo, J.D. Assaf, A. Callejo, B. Feliu, Atilio Navarro, Susana Cedres, Rodrigo Dienstmann, B. Roman, N. Pardo, A. Pedrola, V. Monton, F. Filipi-Arriaga, R. Madrenas, E. Felip, Sergi Recasens, and Alex Martinez-Marti

Subjects
Pulmonary and Respiratory Medicine, Cisplatin, Oncology, medicine.medical_specialty, Pleural mesothelioma, business.industry, Carboplatin, chemistry.chemical_compound, chemistry, Internal medicine, medicine, In patient, business, medicine.drug
Published
2021
Full Text
View/download PDF

25. Immune-Related Gene Expression Profiling After PD-1 Blockade in Non–Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma

Author

Laia Paré, Laura Comerma, Llucia Alos, Paolo Nuciforo, Ana Arance, Noemi Reguart, N. Pardo, Nuria Viñolas, Aleix Prat, Tomás Pascual, Alejandro Navarro, Cheng Fan, Lydia Gaba, Joel S. Parker, Patricia Galván, Enriqueta Felip, Susana Cedres, Ana Vivancos, A. Martinez, and Iván Victoria

Subjects
0301 basic medicine, Cancer Research, Pathology, medicine.medical_specialty, Melanoma, Cancer, Pembrolizumab, Biology, medicine.disease, Head and neck squamous-cell carcinoma, Immune checkpoint, Gene expression profiling, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Oncology, 030220 oncology & carcinogenesis, medicine, Cancer research, Carcinoma, Nivolumab
Abstract

Antibody targeting of the immune checkpoint receptor PD1 produces therapeutic activity in a variety of solid tumors, but most patients exhibit partial or complete resistance to treatment for reasons that are unclear. In this study, we evaluated tumor specimens from 65 patients with melanoma, lung nonsquamous, squamous cell lung or head and neck cancers who were treated with the approved PD1-targeting antibodies pembrolizumab or nivolumab. Tumor RNA before anti-PD1 therapy was analyzed on the nCounter system using the PanCancer 730-Immune Panel, and we identified 23 immune-related genes or signatures linked to response and progression-free survival (PFS). In addition, we evaluated intra- and interbiopsy variability of PD1, PD-L1, CD8A, and CD4 mRNAs and their relationship with tumor-infiltrating lymphocytes (TIL) and PD-L1 IHC expression. Among the biomarkers examined, PD1 gene expression along with 12 signatures tracking CD8 and CD4 T-cell activation, natural killer cells, and IFN activation associated significantly with nonprogressive disease and PFS. These associations were independent of sample timing, drug used, or cancer type. TIL correlated moderately (∼0.50) with PD1 and CD8A mRNA levels and weakly (∼0.35) with CD4 and PD-L1. IHC expression of PD-L1 correlated strongly with PD-L1 (0.90), moderately with CD4 and CD8A, and weakly with PD1. Reproducibility of gene expression in intra- and interbiopsy specimens was very high (total SD

Published
2017
Full Text
View/download PDF

26. Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches

Author

A. Martinez de Castro, Jordi Remon, Enriqueta Felip, Alex Martinez-Marti, Atilio Navarro, N. Pardo, and Susana Cedres

Subjects
0301 basic medicine, Pulmonary and Respiratory Medicine, Oncology, Cancer Research, medicine.medical_specialty, Lung Neoplasms, medicine.medical_treatment, Programmed Cell Death 1 Receptor, Population, Antineoplastic Agents, Pembrolizumab, Antibodies, Monoclonal, Humanized, B7-H1 Antigen, 03 medical and health sciences, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, Internal medicine, medicine, Humans, Lung cancer, education, Randomized Controlled Trials as Topic, Chemotherapy, education.field_of_study, business.industry, Antibodies, Monoclonal, Immunotherapy, medicine.disease, Survival Analysis, Immune checkpoint, Nivolumab, 030104 developmental biology, Clinical Trials, Phase III as Topic, 030220 oncology & carcinogenesis, Biomarker (medicine), business
Abstract

Immune checkpoint inhibitors are considered standard second-line treatment in advanced non-small cell lung cancer patients. This strategy has also become standard in first-line setting for a subgroup of patients with strongly positive PD-L1 tumors; therefore, PD-L1 status might be considered a new biomarker that deserves upfront testing. New combinations of immune checkpoint inhibitors and with chemotherapy have been tested in first-line treatment. However, some questions remain unanswered such as the best treatment strategy or the real upfront efficacy of these therapeutic strategies in the whole lung cancer population. In this review we summarize the main results in the first-line setting of recent phase III trials with immune checkpoint inhibitors in advanced non-small cell lung cancer patients.

Published
2017
Full Text
View/download PDF

27. Simulation based multi-criteria evaluation of design scenarios for an industrial waste heat based micro district heating network supplying standard and low-energy buildings

Author

N. Pardo-Garcia, R. Abdurafikov, Ralf-Roman Schmidt, and Charlotte Marguerite

Subjects
Engineering, 020209 energy, 02 engineering and technology, Civil engineering, Industrial waste, Multi criteria, Waste heat, Thermal, 0202 electrical engineering, electronic engineering, information engineering, Production (economics), SDG 7 - Affordable and Clean Energy, design scenarios, Simulation based, ta218, ta212, ta214, business.industry, micro-district heating, waste heat, SDG 11 - Sustainable Cities and Communities, Booster (electric power), heat storages, business, Efficient energy use
Abstract

This paper presents the results of a multi-criteria evaluation of different design scenarios for a micro-DH network in Vienna, Austria, which involves energy efficient buildings (supplied by heat-pumps and solar thermal panels) and a standard building (equipped with gas boilers). The aim is to assess the integration of industrial waste heat available on-site together with high and low-temperature storages, to balance the heat production and demand, and a heat-pump booster, to supply the network with the required temperature level. The integration of different temperature levels and different profiles from both the production side and consumption side constitute the main challenges.

Published
2017
Full Text
View/download PDF

28. Analysis of mismatch repair (MMR) proteins expression in a series of malignant pleural mesothelioma (MPM) patients

Author

Susana Cedres, A C Zucchiatti, Atilio Navarro, Alex Martinez-Marti, Rodrigo Dienstmann, N. Pardo, A. Callejo, Santiago Ponce-Aix, Luis Paz-Ares, Enriqueta Felip, J.M. Miquel, P. Iranzo, S Gómez-Abecia, Irene Sansano, A.B. Enguita, and Cristina Viaplana

Subjects
0301 basic medicine, Oncology, Adult, Male, Cancer Research, medicine.medical_specialty, Pleural Neoplasms, Population, MLH1, DNA Mismatch Repair, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, PMS2, Humans, education, Immune Checkpoint Inhibitors, Aged, Mismatch Repair Endonuclease PMS2, Retrospective Studies, Aged, 80 and over, education.field_of_study, business.industry, Mesothelioma, Malignant, Microsatellite instability, General Medicine, Middle Aged, medicine.disease, Immunohistochemistry, Survival Analysis, Neoplasm Proteins, MSH6, DNA-Binding Proteins, 030104 developmental biology, MutS Homolog 2 Protein, MSH2, 030220 oncology & carcinogenesis, Biomarker (medicine), Female, Microsatellite Instability, Immunotherapy, business, MutL Protein Homolog 1
Abstract

Promising results have been reported with immune checkpoint inhibitors (ICI) in a small proportion of MPM patients. MMR deficiency (dMMR) has been well described in several malignancies and was approved as a biomarker for anti-PD-1 inhibitors. Next generation sequencing (NGS) data demonstrated that 2% of MPM harbor microsatellite instability. The aim of this study is to characterize MMR by immunohistochemistry (IHC) in a series of MPM including a subset of patients treated with immunotherapy. Tumors of 159 MPM p diagnosed between 2002 and 2017 were reviewed. Formalin-fixed, paraffin-embedded tissue was stained for MLH1, MSH2, MSH6 and PMS2 and tumors were classified as dMMR (MMR protein expression negative) and MMR intact (all MMR proteins positively expressed). We retrospectively collected clinical outcomes under standard chemotherapy and experimental immunotherapy in the entire cohort. MMR protein expression was analyzed in 158 samples with enough tissue and was positive in all of the cases. Twenty two patients received ICI with anti-CTLA4 or anti-PD-1 blockade in clinical trials, 58% had a response or stable disease for more than 6 m, with median progression-free survival (PFS) of 5.7 m (2.1–26.1 m). The median overall survival (mOS) in all population was 15 months (m) (13.5–18.8 m). In a multivariable model factors associated to improved mOS were PS 0, neutrophil–lymphocyte ratio (NLR)

Published
2019

29. Analysis of chemotherapy efficacy according to histology in malignant pleural mesothelioma (MPM) patients (p)

Author

David Humberto Marmolejo Castañeda, Alex Martinez-Marti, Caterina Carbonell, Juan David Assaf Pastrana, Julia Lostes, A. Pedrola, Ramon Amat, N. Pardo, Susana Cedres Perez, Javier Gonzalo, A. Callejo, Rodrigo Dienstmann, Alejandro Navarro, Enriqueta Felip, P. Iranzo, and Joan Frigola

Subjects
Oncology, Cancer Research, Chemotherapy, medicine.medical_specialty, Prognostic factor, business.industry, Pleural mesothelioma, medicine.medical_treatment, Pleural Tumor, Histology, medicine.disease_cause, Systemic therapy, Asbestos, Internal medicine, Medicine, business
Abstract

e20563 Background: MPM is a highly aggressive pleural tumor associated with asbestos exposure and with limited survival despite systemic therapy. Histology is a prognostic factor and recently CheckMate 743 trial demonstrated survival benefit of immunotherapy in first line with some differences in the efficacy of chemotherapy according to histology. However, randomized trials who led to the approval of antifolate in mesothelioma did not include analysis of outcomes by histology. The objective of this study is to characterize the impact of chemotherapy according to histology in p with MPM at our institution. Methods: We review 189 MPM p diagnosed at Vall d´Hebron University Hospital between November 2002 and April 2020. Associations between clinical variables and outcome were assessed with Cox regression models and survival data were calculated by the Kaplan-Meier method. Results: Patient’s characteristics: median age 68 years (y) (45-88 y), males: 70%, performance status (PS)1: 69%, asbestos exposure: 75%, epithelioid subtype: 76%. First line chemotherapy was offered to 85% of p (66% cisplatin-pemetrexed and 27% carboplatin-pemetrexed). Median overall survival (OS) in overall population was 21.3 m (95%CI17.2-24.3). Epithelioid histology, PS 0, neutrophil-lymphocyte ratio

Published
2021
Full Text
View/download PDF

30. 198P Analysis of efficacy of immunotherapy according to histology in malignant pleural mesothelioma (MPM) patients

Author

Alex Martinez-Marti, N. Pardo, J.D. Assaf, D. Marmolejo, H. Bote, A. Navaro, J. Lostes, A. Callejo, P. Iranzo, Susana Cedres, Enriqueta Felip, J. Gonzalo, A. Pedrola, and V. Monton

Subjects
Pulmonary and Respiratory Medicine, Pathology, medicine.medical_specialty, Oncology, business.industry, Pleural mesothelioma, medicine.medical_treatment, Medicine, Histology, Immunotherapy, business
Published
2021
Full Text
View/download PDF

31. 126P Clinical predictive factors in real world setting in advanced non-small cell lung cancer (NSCLC) patients (pts)treated with immune checkpoint inhibitors (ICI)

Author

Alex Martinez-Marti, Joan Frigola, J.D. Assaf, Caterina Carbonell, Susana Cedres, Enriqueta Felip, A. Callejo, N.M. Diaz Mejia, P. Iranzo, D. Marmolejo, N. Pardo, Atilio Navarro, and Ramon Amat

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, business.industry, Immune checkpoint inhibitors, Internal medicine, medicine, non-small cell lung cancer (NSCLC), medicine.disease, business
Published
2021
Full Text
View/download PDF

32. 127P Real-world evidence and clinical characteristics in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICI)

Author

J.D. Assaf, N. Pardo, Joan Frigola, Enriqueta Felip, Susana Cedres, N.M. Diaz Mejia, Alex Martinez-Marti, D. Marmolejo, P. Iranzo, Caterina Carbonell, Atilio Navarro, A. Callejo, and Ramon Amat

Subjects
Pulmonary and Respiratory Medicine, Oncology, business.industry, Immune checkpoint inhibitors, Cancer research, Medicine, non-small cell lung cancer (NSCLC), In patient, business, Real world evidence, medicine.disease
Published
2021
Full Text
View/download PDF

33. Analysis of expression of PTEN/PI3K pathway and programmed cell death ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM)

Author

Santiago Ponce-Aix, N. Pardo-Aranda, Irene Sansano, M.A. Montoro, Enriqueta Felip, A.B. Enguita, Alex Martinez-Marti, Susana Cedres, A. Navarro-Mendivil, and Jon Zugazagoitia

Subjects
Male, Mesothelioma, 0301 basic medicine, Pulmonary and Respiratory Medicine, Oncology, Cancer Research, medicine.medical_specialty, Lung Neoplasms, Pleural Neoplasms, B7-H1 Antigen, Phosphatidylinositol 3-Kinases, 03 medical and health sciences, Prostate cancer, 0302 clinical medicine, Internal medicine, PD-L1, Biomarkers, Tumor, medicine, Humans, PTEN, Pleural Neoplasm, Protein kinase B, PI3K/AKT/mTOR pathway, Aged, Aged, 80 and over, biology, business.industry, Forkhead Box Protein O3, Mesothelioma, Malignant, PTEN Phosphohydrolase, Middle Aged, Prognosis, medicine.disease, 030104 developmental biology, 030220 oncology & carcinogenesis, biology.protein, Cancer research, Immunohistochemistry, Female, business
Abstract

Malignant pleural mesothelioma (MPM) frequently express elevated AKT/mTOR activity. Previous reports in gliomas, colon, breast and prostate cancer suggest that PTEN/PI3K pathway may be important for the induction of PD-L1 expression. This study explored the expression of PTEN/PI3K pathway and PD-L1 in MPM and its relationship with the patient́s prognosisTwenty seven consecutive MPM patients were reviewed. Formalin-fixed, paraffin-embedded tissue biopsies were used for immunohistochemical analysis of PTEN/PI3K pathway and PD-L1 RESULTS: Expression of PTEN, mTOR, pAKT, p4EBP1, peif4E, pS6 and FOXO3a was found in 88.5%, 92.3%, 78.3%, 38.5%, 100%, 52.2% and 100% of tumors and PD-L1 in 23%. We found a significant correlation between pAKT, FOXO3a and PD-L1 expression and longer overall survival (p 0.05). We did not identify significant association between the level of PD-L1 expression and alterations in PI3K pathwayThis study shows PTEN/PI3K pathway and PD-L1 in MPM are frequently activated. Our results suggests that there is not association between PD-L1 and the involvement of the PI3K pathway in MPM.

Published
2016
Full Text
View/download PDF

34. 1910P Outcomes of systemic therapy after first line therapy in patients (p) with malignant pleural mesothelioma (MPM)

Author

Alex Martinez-Marti, A. Pedrola, V. Monton, J. Gonzalo, A. Valdivia, Enriqueta Felip, N. Pardo, P. Iranzo, N. Saoudi Gonzalez, Rodrigo Dienstmann, Atilio Navarro, Susana Cedres, and A. Callejo

Subjects
Oncology, medicine.medical_specialty, First line therapy, business.industry, Pleural mesothelioma, Internal medicine, medicine, In patient, Hematology, business, Systemic therapy
Published
2020
Full Text
View/download PDF

35. 1798P Carboplatin-paclitaxel (CP) chemotheraphy as salvage treatment for small cell lung cancer (SCLC): A real-world evidence analysis

Author

Rodrigo Dienstmann, P. Iranzo, Enriqueta Felip, Nadia Saoudi, N. Pardo, A. Garcia-Alvarez, G. Villacampa Javierre, Alex Martinez-Marti, J.D.D. Assaf Pastrana, Atilio Navarro, Susana Cedres, and A. Callejo

Subjects
Oncology, medicine.medical_specialty, business.industry, Internal medicine, Salvage treatment, Medicine, Hematology, Non small cell, business, Real world evidence, Carboplatin/paclitaxel
Published
2020
Full Text
View/download PDF

36. 1807P Real world data on 442 patients (p) with small cell lung cancer (SCLC) treated in the last ten years at Vall d’Hebron Hospital

Author

Alex Martinez-Marti, P. Iranzo, A. Garcia-Alvarez, A. Callejo, N. Pardo, N. Saoudi Gonzalez, Susana Cedres, Enriqueta Felip, G. Villacampa Javierre, Atilio Navarro, M.J. Lostes Bardaji, Rodrigo Dienstmann, and J.D.D. Assaf Pastrana

Subjects
Oncology, medicine.medical_specialty, business.industry, Internal medicine, medicine, Hematology, Non small cell, business, Real world data
Published
2020
Full Text
View/download PDF

37. 5PSQ-021 Prescription errors associated with on-demand medication reconciliation at admission: sublingual nitroglycerin as an example

Author

I Martinez Aguirre, MJ Yurrebaso Ibarreche, LM Mendarte Barrenechea, M Arrastia Erviti, U Blazquez Urtizberea, N Pardo Santos, I Ibarrola Izquierdo, and JA Dominguez Menendez

Subjects
medicine.medical_specialty, Loperamide, Ebastine, business.industry, Incidence (epidemiology), Retrospective cohort study, Olopatadine, Emergency medicine, medicine, Salbutamol, Section 5: Patient safety and quality assurance, Tramadol, Medical prescription, business, medicine.drug
Abstract

Background In primary care the computerised physician order entry system (CPOES), treatments on demand must have an associated fixed schedule. This is use in order to calculate monthly collection of the medication. At hospital admission, usually on-demand home medication is prescribed with a fixed schedule, causing potential medication errors. Sublingual (sl) nitroglycerin is one of the most implicated drugs in this type of error. Purpose To estimate and analyse the incidence of medication errors due to the incorrect prescription of on-demand home treatment. To analyse the prescription of sl nitroglycerin. Material and methods Retrospective observational study of a 15-day- period. Only patients with home medications (chronic or on-demand) were included, and were reviewed and registered the day after admission. Analgesics and proton-pump inhibitors were excluded because of the high usein hospital. On-demand medication prescribed with a fixed schedule without justification was considered incorrect. Retrospective analysis of sl nitroglycerin prescription over 60 days, excluding patients receiving just one dose, or treatment initiated in hospital. Prescriptions with a fixed schedule and without indications were considered wrong. Prescription correction by pharmacists was also taken into account. Results Home treatment of 122 patients was analysed (average age 69; 62 females; average drugs four). From 488 medications, 25 were prescribed on demand (0.2/patient), and 11 (2.25%) were prescribed in a fixed schedule incorrectly in eight patients. Ten of the mistakes occurred in surgical services (7/48 inpatients), and one in non-surgical services (1/74 inpatients). In six of these, at least one dose was administered. Implicated medicines: terbutaline (two), salbutamol, sl nitroglycerin, mepyramine, tramadol, furosemide, olopatadine, ebastine, mometasone and loperamide. Sl nitroglycerin prescriptions of 30 inpatients were analysed (average age 76; 18 males). Eighteen prescriptions were incorrect (60%): 17 errors in 20 surgical patients and one in non-surgical (psychiatry service). All incorrect prescriptions were corrected by pharmacists at admission, so no medication error occurred. Conclusion CPOES can be a source of new errors, not observed until its introduction, so pharmaceutical validation is essential in its detection and correction. To prevent these mistakes, primary care CPOES modification and continuous practice are necessary, especially in surgical services. No conflict of interest

Published
2018

38. P1.16-05 Incidence and Outcome of Multiple Primary Cancers (MPC) in a Series of Lung Cancer (LC) Patients

Author

Cedres, S., primary, Hernando-Calvo, A., additional, Iranzo, P., additional, Callejo, A., additional, Aranda, N. Pardo, additional, Navarro, A., additional, Martinez-Marti, A., additional, Assaf, J.D., additional, Miquel, J.M., additional, Rodriguez, G., additional, Monton, V., additional, Pedrola, A., additional, Viaplana, C., additional, Carbonell, C., additional, Sanso, M., additional, Dienstmann, R., additional, Amat, R., additional, Vivancos, A., additional, and Felip, E., additional

Published
2019
Full Text
View/download PDF

39. AB0948 Insufficient calcium intake in pediatric population with risk factors for osteoporosis

Author

Enric Carreras, Silvia Herrera, B Lόpez Magallares, M. Torrent, G. Fraga, Ana Marin, Jordi Casademont, J Malouf Sierra, J. Betancourt, and N Pardo

Subjects
Peak bone mass, Anamnesis, medicine.medical_specialty, education.field_of_study, Malabsorption, business.industry, Osteoporosis, Population, chemistry.chemical_element, Calcium, medicine.disease, Surgery, chemistry, Intolerances, Internal medicine, medicine, Risk factor, business, education
Abstract

Background Compliance with daily calcium requirements in paediatric and young age is necessary to acquire peak bone mass, especially in populations that meet one or more risk factors for fractures Objectives To study the characteristics of the pediatric population with at least one risk factor for developing low bone mass/osteoporosis and to measure their calcium intake Methods Demographic and clinical data were prospectively collected from patients aged 2 to 20 years that met at least 1 risk factors for bone fragility, including: inflammatory diseases, treatment with Immunosuppressants and/or corticoesteroids, malabsortive disorders, chronic systemic disorders such as nephropathies or hematologic diseases, etc. The patients or their legal tutors signed the Informed Consent in order to participate in the study. The average daily calcium intake was collected through the Spanish INDICAD 2001 study survey, together with a comprehensive anamnesis. If patients or their family reported taking food not included in the survey, its calcium content were consulted in the Spanish Food Composition Database published by the BEDCA Network of the Ministry of Health Science and Innovation Results Data were collected from 50 patients, with a mean age of 9.2 years (2–20), 28 (56%) female, 86% Caucasian, 6% Arab, 2% Asian and 6% Latin. The most frequent diagnoses were: Food intolerances/malabsorption: 32%, nephropathies: 22%, JIA: 16%, vasculitis: 10%, other inflammatory diseases: 8%. 42% had received systemic corticosteroids at some point, and 16% were receiving corticosteroids at present. Average daily calcium intake was 718 mg/d. They were divided by age groups, attending to daily calcium needs per group. In Table 1 we can observe the Recommended Daily Amount (RDA) of calcium by the Spanish Association of Pediatrics and the consumption collected, by age group. Only 3 children with low calcium intake were taking supplements.A decrease in calcium RDA adherence was observed with increasing age, statistically significant (p=0.009). There was also a lower calcium intake in the non-Caucasians compared to Caucasians statistically significant (p=0.044), which was not associated with age. Conclusions Calcium intake in the population under 21 years old with at least 1 risk factor for developing low bone mass/osteoporosis is lower than recommended. In addition, recommendations are based on the physiological needs of the healthy population and it could be expected to be insufficient for those with chronic diseases. It should be noted that calcium intake in the groups with higher requirements (adolescents and young people) is lower, with a reduction in the proportion of patients who meet the compliance with the RDA as age increases. Studies with a larger population are needed to ratify these results together with serum calcidiol levels Disclosure of Interest None declared

Published
2017
Full Text
View/download PDF

40. Dual MET and ERBB inhibition overcomes intratumor plasticity in osimertinib-resistant-advanced non-small-cell lung cancer (NSCLC)

Author

Gustavo Rodriguez-Esteban, A. Martinez de Castro, Enriqueta Felip, H.G. Palmer, Ana Vivancos, Alex Martinez-Marti, Susana Cedres, Holger Heyn, A. Villanueva, Amy Guillaumet-Adkins, O. Arqués, Jordi Remon, Paolo Nuciforo, Roberta Fasani, Ernest Nadal, J.M. Miquel, Atilio Navarro, Judit Matito, N. Pardo, and Elisabetta Mereu

Subjects
Male, 0301 basic medicine, Lung Neoplasms, Afatinib, non-small cell lung cancer (NSCLC), NSCLC, T790M, Piperazines, Metastasis, Mice, Random Allocation, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, Osimertinib, Pulmons -- Càncer, Aniline Compounds, Brain Neoplasms, Triazines, Imidazoles, Hematology, Proto-Oncogene Proteins c-met, Primary tumor, ErbB Receptors, Oncology, 030220 oncology & carcinogenesis, Benzamides, MET, intratumor plasticity, Female, medicine.drug, Thoracic Tumors, EGFR, Mice, Nude, Pemetrexed, 03 medical and health sciences, Cervell -- Tumors, medicine, Immunitat natural, Animals, Humans, Lung cancer, Protein Kinase Inhibitors, Acrylamides, business.industry, acquired resistance, Original Articles, medicine.disease, Xenograft Model Antitumor Assays, respiratory tract diseases, 030104 developmental biology, Drug Resistance, Neoplasm, Quinazolines, Cancer research, Acquired resistance, Intratumor plasticity, Cisplatin, business, Genètica, Brain metastasis
Abstract

BACKGROUND: Third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) such as osimertinib are the last line of targeted treatment of metastatic non-small-cell lung cancer (NSCLC) EGFR-mutant harboring T790M. Different mechanisms of acquired resistance to third-generation EGFR-TKIs have been proposed. It is therefore crucial to identify new and effective strategies to overcome successive acquired mechanisms of resistance. METHODS: For Amplicon-seq analysis, samples from the index patient (primary and metastasis lesions at different timepoints) as well as the patient-derived orthotopic xenograft tumors corresponding to the different treatment arms were used. All samples were formalin-fixed paraffin-embedded, selected and evaluated by a pathologist. For droplet digital PCR, 20 patients diagnosed with NSCLC at baseline or progression to different lines of TKI therapies were selected. Formalin-fixed paraffin-embedded blocks corresponding to either primary tumor or metastasis specimens were used for analysis. For single-cell analysis, orthotopically grown metastases were dissected from the brain of an athymic nu/nu mouse and cryopreserved at -80°C. RESULTS: In a brain metastasis lesion from a NSCLC patient presenting an EGFR T790M mutation, we detected MET gene amplification after prolonged treatment with osimertinib. Importantly, the combination of capmatinib (c-MET inhibitor) and afatinib (ErbB-1/2/4 inhibitor) completely suppressed tumor growth in mice orthotopically injected with cells derived from this brain metastasis. In those mice treated with capmatinib or afatinib as monotherapy, we observed the emergence of KRAS G12C clones. Single-cell gene expression analyses also revealed intratumor heterogeneity, indicating the presence of a KRAS-driven subclone. We also detected low-frequent KRAS G12C alleles in patients treated with various EGFR-TKIs. CONCLUSION: Acquired resistance to subsequent EGFR-TKI treatment lines in EGFR-mutant lung cancer patients may induce genetic plasticity. We assess the biological insights of tumor heterogeneity in an osimertinib-resistant tumor with acquired MET-amplification and propose new treatment strategies in this situation. This work was supported by the Spanish Ministries of Health and Fondo de Investigación Sanitaria-Fondo Europeo de Desarrollo Regional (FEDER) (PI14/01248, PI13-01339, PIE13/00022, PI16/01898); AECC Scientific Foundation (GCB14-2170); and Fundación Mutua Madrileña (AP150932014). HGP and HH are Miguel Servet researchers funded by the Spanish Institute of Health Carlos III (CPII14/00037, CP14/00229). PN laboratory is funded by the Tumor Biomarker Research Program of the Banco Bilbao Vizcaya Argentaria Foundation (FBBVA)

Published
2017

41. Absence of Relationship between Mitochondrial DNA Haplogroups and Cisplatin-Induced Hearing Loss

Author

D. Graterol, C. Garcia-Vaquero, M. I. Rochera-Villach, Cristina Mir, Alex Lyakhovich, Matilde E. Lleonart, I. Braña, Juan Lorente, and A. N. Pardo

Subjects
0301 basic medicine, Oncology, medicine.medical_specialty, Article Subject, Hearing loss, lcsh:Surgery, Audiology, Haplogroup, 03 medical and health sciences, Ototoxicity, Internal medicine, otorhinolaryngologic diseases, Medicine, Cisplatin, Cardiotoxicity, medicine.diagnostic_test, business.industry, lcsh:RD1-811, General Medicine, lcsh:Otorhinolaryngology, medicine.disease, lcsh:RF1-547, 030104 developmental biology, Cohort, medicine.symptom, Audiometry, business, Research Article, Human mitochondrial DNA haplogroup, medicine.drug
Abstract

Background.Many drugs used for cancer chemotherapy produce reactive oxygen species, thus leading to various complications including nephrotoxicity, cardiotoxicity, and ototoxicity.Objective.We have provided a haplogroup analysis of a cohort of cancer patients treated with chemotherapy and compared factors associated with associated hearing loss.Study Design and Methods.This observational cohort study includes a pure-tone audiometry of the patients who underwent chemotherapeutic treatment. Medical history, presence of risk factors for hearing loss, toxic habits, and association with haplogroups have been determined.Results.40% of patients developed hearing loss after administration of cisplatin, which was bilateral and symmetrical and of high frequencies. The most frequent haplogroup was H with a slight overexpression of groups V and K and a low frequency of groups J and T. No association of the haplogroup types with the hearing loss has been found; however age was revealed as an important determining factor.Conclusions.Ototoxicity caused by cisplatin is manifested as bilateral, symmetrical, and predominantly high frequency hearing loss. Although we did not find a strong correlation of haplogroups with ototoxicity, our results revealed the existence of a risk group of elderly patients over 60, which are more susceptible to hearing loss induced by cisplatin, than young adults, regardless of preexisting hearing loss.

Published
2017
Full Text
View/download PDF

42. 219P Outcomes of malignant pleural mesothelioma (MPM) patients (p) treated after first line chemotherapy (CT)

Author

N. Pardo, Alex Martinez-Marti, E. Felip Font, J.M. Miquel, Atilio Navarro, Rodrigo Dienstmann, Guillermo Villacampa, J. Remon-Masip, Susana Cedres, and Fabiola Amair

Subjects
Pulmonary and Respiratory Medicine, medicine.medical_specialty, Oncology, business.industry, Pleural mesothelioma, Medicine, Radiology, First line chemotherapy, business
Published
2018
Full Text
View/download PDF

43. WNT pathway mutations (APC/CTNNB1) and immune checkpoint inhibitors (ICI) response in metastatic non-small cell lung cancer (NSCLC) patients

Author

H.G. Palmer, A. Martinez, Ana Vivancos, Rodrigo Dienstmann, Enriqueta Felip, P. Iranzo, N. Pardo, A. Pedrola, Atilio Navarro, F.J. Ros Montañá, A. Callejo, R. Amat, Susana Cedres, and Caterina Carbonell

Subjects
medicine.medical_specialty, business.industry, Funding grant, Immune checkpoint inhibitors, Immune resistance, Hematology, First line treatment, Second line, Oncology, Family medicine, Technology transfer, medicine, Overall survival, business, health care economics and organizations, Predictive biomarker
Abstract

Background WNT pathway mutations (mut) are uncommon in NSCLC. Recent preclinical studies suggest that APC/CTNNB1 mut induce immune resistance in lung adenocarcinoma but how they may impact on immunotherapy response in the clinics remains unclear. Objective: our aim is to describe the clinical outcomes - Overall survival (OS) and progression-free-survival (PFS) and response rate (RR) - of a metastatic NSCLC cohort with APC/CTNNB1 mut treated with immunotherapy. Methods We selected those patients with metastatic NSCLC and APC or CTNNB1 mut detected through Amplicon-Seq (tissue), Foundation (plasma), Guardant (plasma) or exome sequencing (tissue) performed from 2014 to 2018. Results Incidence of APC/CTNNB1 mut in NSCLC in our hospital has been 1,26% and 0,7% respectively by Amplicon-Seq (tissue) and 10.4% and 1.04% respectively by exome sequencing (tissue). We identified 27 patients with APC (81%) or CTNNB1 (19%) mutations. The median age of the patients was 59 years (44-74), 72% of them were male and most frequent histology was adenocarcinoma (66%). Fifteen of the patients received ICI, 27% as a first line treatment and 47% as a second line. Interestingly, 1 patient had EGFR mut (exon 19 and 20) and 4 patients had KRAS mut. Median OS of the whole cohort from date of diagnosis was 24.5 months (CI95% 13.7-NA). Median OS was 23.5 months (CI95% 10.4-NA) for those patients who harboured CTNNB1 mut and 57.3 months (CI95% 13.7-NA) for those patients with APC mut (HR 1.8, CI95% 0.32-10, p = 0.5). Median PFS with ICI was 6.6 months (CI95% 0.9-NA). Median PFS was 0.7 months (CI95% 0.5-NA) for those patients with CTNNB1 mut and 8.9 months (CI95% 1.8-NA) with APC mut (HR 6.7, CI95% 1.1-41, p = 0.04). None of the 2 CTNNB1 mut patients responded to ICI, while RR in the APC mut cohort was 30% (4 out of 13). Conclusions In our cohort, APC mut did not show to impair clinical outcomes. Few CTNNB1 mut cases hinder conclusive analyses. Correlation with other predictive biomarkers such as tumor mutation burden and PDL1 expression is ongoing. Legal entity responsible for the study Vall d´Hebron Institute of Oncology (VHIO). Funding Grant from: Carlos III Institute of Health, Madrid, Spain: PI14/01248 and PI17/00938. Disclosure P. Iranzo: Advisory / Consultancy, Travel / Accommodation / Expenses: BMS; Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Advisory / Consultancy, Travel / Accommodation / Expenses: Merck; Advisory / Consultancy, Travel / Accommodation / Expenses: Boehringer; Advisory / Consultancy, Travel / Accommodation / Expenses: MSD; Advisory / Consultancy: Rovi; Advisory / Consultancy: Kyowa Kirin; Advisory / Consultancy, Travel / Accommodation / Expenses: Grunental. A. Callejo: Advisory / Consultancy, Travel / Accommodation / Expenses: BMS; Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer; Advisory / Consultancy, Travel / Accommodation / Expenses: Boehringer; Advisory / Consultancy, Travel / Accommodation / Expenses: MSD; Advisory / Consultancy: Kyowa kirin; Travel / Accommodation / Expenses: Celgene. N. Pardo: Advisory / Consultancy: BMS; Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer; Advisory / Consultancy: Boehringer. A. Martinez: Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: BMS; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Roche; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: MSD; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Pfizer; Advisory / Consultancy, Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Boehringer. A. Navarro: Advisory / Consultancy, Travel / Accommodation / Expenses: BMS; Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer; Advisory / Consultancy, Travel / Accommodation / Expenses: Boehringer; Advisory / Consultancy: Oryzon Genomics; Travel / Accommodation / Expenses: MSD. S. Cedres: Advisory / Consultancy: BMS; Advisory / Consultancy, Travel / Accommodation / Expenses: Roche; Advisory / Consultancy, Travel / Accommodation / Expenses: Pfizer ; Advisory / Consultancy, Travel / Accommodation / Expenses: Boehringer; Advisory / Consultancy: MSD; Advisory / Consultancy: Amphera. R. Dienstmann: Advisory / Consultancy, Speaker Bureau / Expert testimony: Roche; Speaker Bureau / Expert testimony: Symphogen; Speaker Bureau / Expert testimony: Ipsen; Speaker Bureau / Expert testimony: Amgen; Speaker Bureau / Expert testimony: Sanofi; Speaker Bureau / Expert testimony: MSD; Speaker Bureau / Expert testimony: Servier; Research grant / Funding (institution): Merck. H.G. Palmer: Research grant / Funding (institution): Bayer; Research grant / Funding (institution): Blueprint; Research grant / Funding (institution): Merus; Research grant / Funding (institution): Cellestia. A. Vivancos: Advisory / Consultancy, Research grant / Funding (institution): SYSMEX; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Advisory / Consultancy: MERCK; Advisory / Consultancy, Research grant / Funding (institution): Roche; Advisory / Consultancy, Research grant / Funding (institution): BMS; Advisory / Consultancy: Guardant Health; Licensing / Royalties, Technology Transfer DX Field: Ferrer; Research grant / Funding (institution): DEBIO; Research grant / Funding (institution): Cellestia; Research grant / Funding (institution): Chittern. E. Felip: Advisory / Consultancy: Abbvie; Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: Blueprint Medicines; Advisory / Consultancy: Boehringer Ingelheim,; Advisory / Consultancy: Bristol-Myers Squibb; Advisory / Consultancy: Celgene; Advisory / Consultancy: Eli Lilly; Advisory / Consultancy: Guardant Health; Advisory / Consultancy: Janssen; Advisory / Consultancy: Medscape; Advisory / Consultancy: Merck KGaA; Advisory / Consultancy: Merck Sharp & Dohme; Advisory / Consultancy: Novartis; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Roche; Advisory / Consultancy: Takeda; Advisory / Consultancy: Touchtime; Research grant / Funding (institution): Fundacion Merck Salud; Research grant / Funding (institution): Grant for Oncology Innovation EMD Serono. All other authors have declared no conflicts of interest.

Published
2019
Full Text
View/download PDF

44. P1.16-05 Incidence and Outcome of Multiple Primary Cancers (MPC) in a Series of Lung Cancer (LC) Patients

Author

Atilio Navarro, Caterina Carbonell, Enriqueta Felip, J.D. Assaf, G. Rodriguez, N. Pardo Aranda, Rodrigo Dienstmann, Ana Vivancos, A. Hernando-Calvo, A. Pedrola, Cristina Viaplana, V. Monton, M. Sanso, P. Iranzo, Susana Cedres, Ramon Amat, A. Callejo, J.M. Miquel, and Alex Martinez-Marti

Subjects
Pulmonary and Respiratory Medicine, Oncology, medicine.medical_specialty, Series (stratigraphy), business.industry, Internal medicine, Incidence (epidemiology), medicine, Lung cancer, medicine.disease, business, Outcome (game theory)
Published
2019
Full Text
View/download PDF

45. EP28.19: Ovarian ectopic pregnancy after tubal ectopic pregnancy

Author

N. Pardo, Eran Kassif, Y. Bar‐Shavit, I. Zilberman Ron, M. Oren, Sharon Perlman, and M. Spira

Subjects
Gynecology, medicine.medical_specialty, Reproductive Medicine, Radiological and Ultrasound Technology, Ectopic pregnancy, business.industry, medicine, Tubal ectopic pregnancy, Obstetrics and Gynecology, Radiology, Nuclear Medicine and imaging, General Medicine, medicine.disease, business
Published
2019
Full Text
View/download PDF

46. Whole exome sequencing (WES) of non-small cell lung cancer (NSCLC) for tumor mutational burden (TMB) analysis and long-term benefit to immune checkpoint inhibitors (ICIs)

Author

Enriqueta Felip, José Antonio Jiménez, J.D. Assaf, Alex Martinez Marti, Paolo Nuciforo, Javier Ros, Miriam Sansó, A. Callejo, Francesco M. Mancuso, Ana Vivancos, A. Pedrola, Rodrigo Dienstmann, N. Pardo, Ramon Amat, Susana Cedres, Cristina Viaplana, Alejandro Navarro, and Irene Sansano

Subjects
Cancer Research, business.industry, Immune checkpoint inhibitors, non-small cell lung cancer (NSCLC), medicine.disease, 03 medical and health sciences, 0302 clinical medicine, Oncology, 030220 oncology & carcinogenesis, Cancer research, Medicine, business, Exome sequencing, 030215 immunology
Abstract

9071 Background: ICIs have significantly changed the therapeutic landscape of advanced NSCLC. As such, characterizing predictive markers of long-term clinical benefit is a critical objective. TMB quantification using targeted gene panels associates with long-term response to ICIs in NSCLC patients (Rizvi H ASCO 18). Although TMB quantified by targeted NGS correlates with that of WES, caution may be needed when using smaller panels. Methods: Here we analyzed WES of tumors and matched normal tissue from 67 NSCLC patients including 42 treated with ICIs. We correlated TMB with clinico-pathological features and outcomes. TMB was categorized as high vs. low according to the upper quartile of cohort distribution. Results: The median TMB was 2.68 non-synonymous variants (nSNVs)/Mb, ranging from 0 to 15.6 nSNVs/Mb, with upper quartile at 5.42 nSNVs/Mb. TMB was higher for smoker/current smoker (median 3.51) compared to never smokers (median 0.94, p = 0.0048) but no differences were seen in elderly ( > 70 years) vs. young patients or across histologies (squamous, adeno and other) and stages at diagnosis. In patients treated with ICIs, median TMB was 5.44 for those achieving complete response, 3.87 for patients with partial response and 2.42 for patients with progressive disease (PD) (p = 0.04). Moreover, improved clinical outcomes were associated with higher TMB (Table). In patients treated with ICIs, TMB as continuous variable had an impact on progression free survival (PFS) (p = 0.03). Median PFS was 22.3 months (mo) (14-not reached) for those with high TMB and 6.4 mo (3-16) for those with low TMB (HR 0.34, 0.13-0.9, p = 0.03). Median overall survival was not reached for those patients with high TMB and 32 mo (22-43) for those with low TMB (HR 0.29, 0.1-0.86, p = 0.02). Conclusions: High TMB correlates with long-term ICI benefit in NSCLC patients. Mutations in individual genes potentially linked to long-term benefit or resistance to ICIs will be presented. [Table: see text]

Published
2019
Full Text
View/download PDF

48. Outcome prognostic factors in inoperable malignant bowel obstruction

Author

Albert Font, Maria de los Llanos Gil, Jose Luis Cuadra Urteaga, Alberto Indacochea, Margarita Romeo, Sara Ahlal, Laia Vilà, Joaquim Radua, N. Pardo, and Albert Tuca

Subjects
Male, Prognostic factor, medicine.medical_specialty, Octreotide, Logistic regression, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Statistical significance, Internal medicine, Intestinal Neoplasms, medicine, Humans, 030212 general & internal medicine, Severe complication, Peritoneal Neoplasms, Hyoscine butylbromide, business.industry, Palliative Care, Middle Aged, medicine.disease, Prognosis, Peritoneal carcinomatosis, Surgery, Bowel obstruction, Oncology, 030220 oncology & carcinogenesis, Female, business, Intestinal Obstruction, medicine.drug
Abstract

Inoperable malignant bowel obstruction (MBO), a severe complication of peritoneal carcinomatosis, has a low desobstruction rate (30–40 %) and end-of-life decision-making is hampered by the lack of known prognostic factors. This study aimed to explore prognostic factors for desobstruction in MBO. All patients with inoperable MBO admitted in our large oncology hospital between 2010 and 2013 were treated following a clinical protocol based on antiemetics, steroids and two antisecretories, octreotide, and hyoscine butylbromide. Two prognostic factor analyses using logistic regressions were performed, one based on data from day 1 of admission and the other on data from day 8. Forty-five patients were included. Frequency of desobstruction was 48.9 %. In the analysis of prognostic factors on day 1, MBO episodes derived from functional physiopathologic mechanisms (vs. mechanic or mixed) were more prone to resolve (p

Published
2016

49. Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356

Author

Klionsky, D.J. Abdelmohsen, K. Abe, A. Abedin, M.J. Abeliovich, H. Arozena, A.A. Adachi, H. Adams, C.M. Adams, P.D. Adeli, K. Adhihetty, P.J. Adler, S.G. Agam, G. Agarwal, R. Aghi, M.K. Agnello, M. Agostinis, P. Aguilar, P.V. Aguirre-Ghiso, J. Airoldi, E.M. Ait-Si-Ali, S. Akematsu, T. Akporiaye, E.T. Al-Rubeai, M. Albaiceta, G.M. Albanese, C. Albani, D. Albert, M.L. Aldudo, J. Algül, H. Alirezaei, M. Alloza, I. Almasan, A. Almonte-Beceril, M. Alnemri, E.S. Alonso, C. Altan-Bonnet, N. Altieri, D.C. Alvarez, S. Alvarez-Erviti, L. Alves, S. Amadoro, G. Amano, A. Amantini, C. Ambrosio, S. Amelio, I. Amer, A.O. Amessou, M. Amon, A. An, Z. Anania, F.A. Andersen, S.U. Andley, U.P. Andreadi, C.K. Andrieu-Abadie, N. Anel, A. Ann, D.K. Anoopkumar-Dukie, S. Antonioli, M. Aoki, H. Apostolova, N. Aquila, S. Aquilano, K. Araki, K. Arama, E. Aranda, A. Araya, J. Arcaro, A. Arias, E. Arimoto, H. Ariosa, A.R. Armstrong, J.L. Arnould, T. Arsov, I. Asanuma, K. Askanas, V. Asselin, E. Atarashi, R. Atherton, S.S. Atkin, J.D. Attardi, L.D. Auberger, P. Auburger, G. Aurelian, L. Autelli, R. Avagliano, L. Avantaggiati, M.L. Avrahami, L. Azad, N. Awale, S. Bachetti, T. Backer, J.M. Bae, D.-H. Bae, J.-S. Bae, O.-N. Bae, S.H. Baehrecke, E.H. Baek, S.-H. Baghdiguian, S. Bagniewska-Zadworna, A. Bai, H. Bai, J. Bai, X.-Y. Bailly, Y. Balaji, K.N. Balduini, W. Ballabio, A. Balzan, R. Banerjee, R. Bánhegyi, G. Bao, H. Barbeau, B. Barrachina, M.D. Barreiro, E. Bartel, B. Bartolomé, A. Bassham, D.C. Bassi, M.T. Bast, R.C., Jr. Basu, A. Batista, M.T. Batoko, H. Battino, M. Bauckman, K. Baumgarner, B.L. Bayer, K.U. Beale, R. Beaulieu, J.-F. Beck, G.R., Jr. Becker, C. Beckham, J.D. Bédard, P.-A. Bednarski, P.J. Begley, T.J. Behl, C. Behrends, C. Behrens, G.M.N. Behrns, K.E. Bejarano, E. Belaid, A. Belleudi, F. Bénard, G. Berchem, G. Bergamaschi, D. Bergami, M. Berkhout, B. Berliocchi, L. Bernard, A. Bernard, M. Bernassola, F. Bertolotti, A. Bess, A.S. Besteiro, S. Bettuzzi, S. Bhalla, S. Bhattacharyya, S. Bhutia, S.K. Biagosch, C. Bianchi, M.W. Biard-Piechaczyk, M. Billes, V. Bincoletto, C. Bingol, B. Bird, S.W. Bitoun, M. Bjedov, I. Blackstone, C. Blanc, L. Blanco, G.A. Blomhoff, H.K. Boada-Romero, E. Böckler, S. Boes, M. Boesze-Battaglia, K. Boise, L.H. Bolino, A. Boman, A. Bonaldo, P. Bordi, M. Bosch, J. Botana, L.M. Botti, J. Bou, G. Bouché, M. Bouchecareilh, M. Boucher, M.-J. Boulton, M.E. Bouret, S.G. Boya, P. Boyer-Guittaut, M. Bozhkov, P.V. Brady, N. Braga, V.M.M. Brancolini, C. Braus, G.H. Bravo-San-Pedro, J.M. Brennan, L.A. Bresnick, E.H. Brest, P. Bridges, D. Bringer, M.-A. Brini, M. Brito, G.C. Brodin, B. Brookes, P.S. Brown, E.J. Brown, K. Broxmeyer, H.E. Bruhat, A. Brum, P.C. Brumell, J.H. Brunetti-Pierri, N. Bryson-Richardson, R.J. Buch, S. Buchan, A.M. Budak, H. Bulavin, D.V. Bultman, S.J. Bultynck, G. Bumbasirevic, V. Burelle, Y. Burke, R.E. Burmeister, M. Bütikofer, P. Caberlotto, L. Cadwell, K. Cahova, M. Cai, D. Cai, J. Cai, Q. Calatayud, S. Camougrand, N. Campanella, M. Campbell, G.R. Campbell, M. Campello, S. Candau, R. Caniggia, I. Cantoni, L. Cao, L. Caplan, A.B. Caraglia, M. Cardinali, C. Cardoso, S.M. Carew, J.S. Carleton, L.A. Carlin, C.R. Carloni, S. Carlsson, S.R. Carmona-Gutierrez, D. Carneiro, L.A.M. Carnevali, O. Carra, S. Carrier, A. Carroll, B. Casas, C. Casas, J. Cassinelli, G. Castets, P. Castro-Obregon, S. Cavallini, G. Ceccherini, I. Cecconi, F. Cederbaum, A.I. Ceña, V. Cenci, S. Cerella, C. Cervia, D. Cetrullo, S. Chaachouay, H. Chae, H.-J. Chagin, A.S. Chai, C.-Y. Chakrabarti, G. Chamilos, G. Chan, E.Y.W. Chan, M.T.V. Chandra, D. Chandra, P. Chang, C.-P. Chang, R.C.-C. Chang, T.Y. Chatham, J.C. Chatterjee, S. Chauhan, S. Che, Y. Cheetham, M.E. Cheluvappa, R. Chen, C.-J. Chen, G. Chen, G.-C. Chen, G. Chen, H. Chen, J.W. Chen, J.-K. Chen, M. Chen, M. Chen, P. Chen, Q. Chen, Q. Chen, S.-D. Chen, S. Chen, S.S.-L. Chen, W. Chen, W.-J. Chen, W.Q. Chen, W. Chen, X. Chen, Y.-H. Chen, Y.-G. Chen, Y. Chen, Y. Chen, Y. Chen, Y.-J. Chen, Y.-Q. Chen, Y. Chen, Z. Chen, Z. Cheng, A. Cheng, C.H.K. Cheng, H. Cheong, H. Cherry, S. Chesney, J. Cheung, C.H.A. Chevet, E. Chi, H.C. Chi, S.-G. Chiacchiera, F. Chiang, H.-L. Chiarelli, R. Chiariello, M. Chieppa, M. Chin, L.-S. Chiong, M. Chiu, G.N.C. Cho, D.-H. Cho, S.-G. Cho, W.C. Cho, Y.-Y. Cho, Y.-S. Choi, A.M.K. Choi, E.-J. Choi, E.-K. Choi, J. Choi, M.E. Choi, S.-I. Chou, T.-F. Chouaib, S. Choubey, D. Choubey, V. Chow, K.-C. Chowdhury, K. Chu, C.T. Chuang, T.-H. Chun, T. Chung, H. Chung, T. Chung, Y.-L. Chwae, Y.-J. Cianfanelli, V. Ciarcia, R. Ciechomska, I.A. Ciriolo, M.R. Cirone, M. Claerhout, S. Clague, M.J. Cl� ria, J. Clarke, P.G.H. Clarke, R. Clementi, E. Cleyrat, C. Cnop, M. Coccia, E.M. Cocco, T. Codogno, P. Coers, J. Cohen, E.E.W. Colecchia, D. Coletto, L. Coll, N.S. Colucci-Guyon, E. Comincini, S. Condello, M. Cook, K.L. Coombs, G.H. Cooper, C.D. Cooper, J.M. Coppens, I. Corasaniti, M.T. Corazzari, M. Corbalan, R. Corcelle-Termeau, E. Cordero, M.D. Corral-Ramos, C. Corti, O. Cossarizza, A. Costelli, P. Costes, S. Cotman, S.L. Coto-Montes, A. Cottet, S. Couve, E. Covey, L.R. Cowart, L.A. Cox, J.S. Coxon, F.P. Coyne, C.B. Cragg, M.S. Craven, R.J. Crepaldi, T. Crespo, J.L. Criollo, A. Crippa, V. Cruz, M.T. Cuervo, A.M. Cuezva, J.M. Cui, T. Cutillas, P.R. Czaja, M.J. Czyzyk-Krzeska, M.F. Dagda, R.K. Dahmen, U. Dai, C. Dai, W. Dai, Y. Dalby, K.N. Valle, L.D. Dalmasso, G. D'amelio, M. Damme, M. Darfeuille-Michaud, A. Dargemont, C. Darley-Usmar, V.M. Dasarathy, S. Dasgupta, B. Dash, S. Dass, C.R. Davey, H.M. Davids, L.M. Dávila, D. Davis, R.J. Dawson, T.M. Dawson, V.L. Daza, P. de Belleroche, J. de Figueiredo, P. de Figueiredo, R.C.B.Q. de la Fuente, J. De Martino, L. De Matteis, A. De Meyer, G.R.Y. De Milito, A. De Santi, M. de Souza, W. De Tata, V. De Zio, D. Debnath, J. Dechant, R. Decuypere, J.-P. Deegan, S. Dehay, B. Del Bello, B. Del Re, D.P. Delage-Mourroux, R. Delbridge, L.M.D. Deldicque, L. Delorme-Axford, E. Deng, Y. Dengjel, J. Denizot, M. Dent, P. Der, C.J. Deretic, V. Derrien, B. Deutsch, E. Devarenne, T.P. Devenish, R.J. Di Bartolomeo, S. Di Daniele, N. Di Domenico, F. Di Nardo, A. Di Paola, S. Di Pietro, A. Di Renzo, L. Di Antonio, A. Díaz-Araya, G. Díaz-Laviada, I. Diaz-Meco, M.T. Diaz-Nido, J. Dickey, C.A. Dickson, R.C. Diederich, M. Digard, P. Dikic, I. Dinesh-Kumar, S.P. Ding, C. Ding, W.-X. Ding, Z. Dini, L. Distler, J.H.W. Diwan, A. Djavaheri-Mergny, M. Dmytruk, K. Dobson, R.C.J. Doetsch, V. Dokladny, K. Dokudovskaya, S. Donadelli, M. Dong, X.C. Dong, X. Dong, Z. Donohue, T.M., Jr. Donohue-Jr, T.M. Doran, K.S. D'orazi, G. Dorn, G.W., II Dosenko, V. Dridi, S. Drucker, L. Du, J. Du, L.-L. Du, L. du Toit, A. Dua, P. Duan, L. Duann, P. Dubey, V.K. Duchen, M.R. Duchosal, M.A. Duez, H. Dugail, I. Dumit, V.I. Duncan, M.C. Dunlop, E.A. Dunn, W.A., Jr. Dupont, N. Dupuis, L. Durán, R.V. Durcan, T.M. Duvezin-Caubet, S. Duvvuri, U. Eapen, V. Ebrahimi-Fakhari, D. Echard, A. Eckhart, L. Edelstein, C.L. Edinger, A.L. Eichinger, L. Eisenberg, T. Eisenberg-Lerner, A. Eissa, N.T. El-Deiry, W.S. El-Khoury, V. Elazar, Z. Eldar-Finkelman, H. Elliott, C.J.H. Emanuele, E. Emmenegger, U. Engedal, N. Engelbrecht, A.-M. Engelender, S. Enserink, J.M. Erdmann, R. Erenpreisa, J. Eri, R. Eriksen, J.L. Erman, A. Escalante, R. Eskelinen, E.-L. Espert, L. Esteban-Martínez, L. Evans, T.J. Fabri, M. Fabrias, G. Fabrizi, C. Facchiano, A. Færgeman, N.J. Faggioni, A. Fairlie, W.D. Fan, C. Fan, D. Fan, J. Fang, S. Fanto, M. Fanzani, A. Farkas, T. Faure, M. Favier, F.B. Fearnhead, H. Federici, M. Fei, E. Felizardo, T.C. Feng, H. Feng, Y. Feng, Y. Ferguson, T.A. Fernández, Á.F. Fernandez-Barrena, M.G. Fernandez-Checa, J.C. Fernández-López, A. Fernandez-Zapico, M.E. Feron, O. Ferraro, E. Ferreira-Halder, C.V. Fesus, L. Feuer, R. Fiesel, F.C. Filippi-Chiela, E.C. Filomeni, G. Fimia, G.M. Fingert, J.H. Finkbeiner, S. Finkel, T. Fiorito, F. Fisher, P.B. Flajolet, M. Flamigni, F. Florey, O. Florio, S. Floto, R.A. Folini, M. Follo, C. Fon, E.A. Fornai, F. Fortunato, F. Fraldi, A. Franco, R. Francois, A. François, A. Frankel, L.B. Fraser, I.D.C. Frey, N. Freyssenet, D.G. Frezza, C. Friedman, S.L. Frigo, D.E. Fu, D. Fuentes, J.M. Fueyo, J. Fujitani, Y. Fujiwara, Y. Fujiya, M. Fukuda, M. Fulda, S. Fusco, C. Gabryel, B. Gaestel, M. Gailly, P. Gajewska, M. Galadari, S. Galili, G. Galindo, I. Galindo, M.F. Galliciotti, G. Galluzzi, L. Galluzzi, L. Galy, V. Gammoh, N. Gandy, S. Ganesan, A.K. Ganesan, S. Ganley, I.G. Gannagé, M. Gao, F.-B. Gao, F. Gao, J.-X. Nannig, L.G. Véscovi, E.G. Garcia-Macía, M. Garcia-Ruiz, C. Garg, A.D. Garg, P.K. Gargini, R. Gassen, N.C. Gatica, D. Gatti, E. Gavard, J. Gavathiotis, E. Ge, L. Ge, P. Ge, S. Gean, P.-W. Gelmetti, V. Genazzani, A.A. Geng, J. Genschik, P. Gerner, L. Gestwicki, J.E. Gewirtz, D.A. Ghavami, S. Ghigo, E. Ghosh, D. Giammarioli, A.M. Giampieri, F. Giampietri, C. Giatromanolaki, A. Gibbings, D.J. Gibellini, L. Gibson, S.B. Ginet, V. Giordano, A. Giorgini, F. Giovannetti, E. Girardin, S.E. Gispert, S. Giuliano, S. Gladson, C.L. Glavic, A. Gleave, M. Godefroy, N. Gogal, R.M., Jr. Gokulan, K. Goldman, G.H. Goletti, D. Goligorsky, M.S. Gomes, A.V. Gomes, L.C. Gomez, H. Gomez-Manzano, C. Gómez-Sánchez, R. Gonçalves, D.A.P. Goncu, E. Gong, Q. Gongora, C. Gonzalez, C.B. Gonzalez-Alegre, P. Gonzalez-Cabo, P. González-Polo, R.A. Goping, I.S. Gorbea, C. Gorbunov, N.V. Goring, D.R. Gorman, A.M. Gorski, S.M. Goruppi, S. Goto-Yamada, S. Gotor, C. Gottlieb, R.A. Gozes, I. Gozuacik, D. Graba, Y. Graef, M. Granato, G.E. Grant, G.D. Grant, S. Gravina, G.L. Green, D.R. Greenhough, A. Greenwood, M.T. Grimaldi, B. Gros, F. Grose, C. Groulx, J.-F. Gruber, F. Grumati, P. Grune, T. Guan, J.-L. Guan, K.-L. Guerra, B. Guillen, C. Gulshan, K. Gunst, J. Guo, C. Guo, L. Guo, M. Guo, W. Guo, X.-G. Gust, A.A. Gustafsson, Å.B. Gutierrez, E. Gutierrez, M.G. Gwak, H.-S. Haas, A. Haber, J.E. Hadano, S. Hagedorn, M. Hahn, D.R. Halayko, A.J. Hamacher-Brady, A. Hamada, K. Hamai, A. Hamann, A. Hamasaki, M. Hamer, I. Hamid, Q. Hammond, E.M. Han, F. Han, W. Handa, J.T. Hanover, J.A. Hansen, M. Harada, M. Harhaji-Trajkovic, L. Harper, J.W. Harrath, A.H. Harris, A.L. Harris, J. Hasler, U. Hasselblatt, P. Hasui, K. Hawley, R.G. Hawley, T.S. He, C. He, C.Y. He, F. He, G. He, R.-R. He, X.-H. He, Y.-W. He, Y.-Y. Heath, J.K. Hébert, M.-J. Heinzen, R.A. Helgason, G.V. Hensel, M. Henske, E.P. Her, C. Herman, P.K. Hernández, A. Hernandez, C. Hernández-Tiedra, S. Hetz, C. Hiesinger, P.R. Higaki, K. Hilfiker, S. Hill, B.G. Hill, J.A. Hill, W.D. Hino, K. Hofius, D. Hofman, P. Höglinger, G.U. Höhfeld, J. Holz, M.K. Hong, Y. Hood, D.A. Hoozemans, J.J.M. Hoppe, T. Hsu, C. Hsu, C.-Y. Hsu, L.-C. Hu, D. Hu, G. Hu, H.-M. Hu, H. Hu, M.C. Hu, Y.-C. Hu, Z.-W. Hua, F. Hua, Y. Huang, C. Huang, H.-L. Huang, K.-H. Huang, K.-Y. Huang, S. Huang, S. Huang, W.-P. Huang, Y.-R. Huang, Y. Huang, Y. Huber, T.B. Huebbe, P. Huh, W.-K. Hulmi, J.J. Hur, G.M. Hurley, J.H. Husak, Z. Hussain, S.N.A. Hussain, S. Hwang, J.J. Hwang, S. Hwang, T.I.S. Ichihara, A. Imai, Y. Imbriano, C. Inomata, M. Into, T. Iovane, V. Iovanna, J.L. Iozzo, R.V. Ip, N.Y. Irazoqui, J.E. Iribarren, P. Isaka, Y. Isakovic, A.J. Ischiropoulos, H. Isenberg, J.S. Ishaq, M. Ishida, H. Ishii, I. Ishmael, J.E. Isidoro, C. Isobe, K.-I. Isono, E. Issazadeh-Navikas, S. Itahana, K. Itakura, E. Ivanov, A.I. Iyer, A.K.V. Izquierdo, J.M. Izumi, Y. Izzo, V. Jäättelä, M. Jaber, N. Jackson, D.J. Jackson, W.T. Jacob, T.G. Jacques, T.S. Jagannath, C. Jain, A. Jana, N.R. Jang, B.K. Jani, A. Janji, B. Jannig, P.R. Jansson, P.J. Jean, S. Jendrach, M. Jeon, J.-H. Jessen, N. Jeung, E.-B. Jia, K. Jia, L. Jiang, H. Jiang, H. Jiang, L. Jiang, T. Jiang, X. Jiang, X. Jiang, Y. Jiang, Y. Jiménez, A. Jin, C. Jin, H. Jin, L. Jin, M. Jin, S. Jinwal, U.K. Jo, E.-K. Johansen, T. Johnson, D.E. Johnson, G.V.W. Johnson, J.D. Jonasch, E. Jones, C. Joosten, L.A.B. Jordan, J. Joseph, A.-M. Joseph, B. Joubert, A.M. Ju, D. Ju, J. Juan, H.-F. Juenemann, K. Juhász, G. Jung, H.S. Jung, J.U. Jung, Y.-K. Jungbluth, H. Justice, M.J. Jutten, B. Kaakoush, N.O. Kaarniranta, K. Kaasik, A. Kabuta, T. Kaeffer, B. Kågedal, K. Kahana, A. Kajimura, S. Kakhlon, O. Kalia, M. Kalvakolanu, D.V. Kamada, Y. Kambas, K. Kaminskyy, V.O. Kampinga, H.H. Kandouz, M. Kang, C. Kang, R. Kang, T.-C. Kanki, T. Kanneganti, T.-D. Kanno, H. Kanthasamy, A.G. Kantorow, M. Kaparakis-Liaskos, M. Kapuy, O. Karantza, V. Karim, M.R. Karmakar, P. Kaser, A. Kaushik, S. Kawula, T. Kaynar, A.M. Ke, P.-Y. Ke, Z.-J. Kehrl, J.H. Keller, K.E. Kemper, J.K. Kenworthy, A.K. Kepp, O. Kern, A. Kesari, S. Kessel, D. Ketteler, R. Kettelhut, I.C. Khambu, B. Khan, M.M. Khandelwal, V.K.M. Khare, S. Kiang, J.G. Kiger, A.A. Kihara, A. Kim, A.L. Kim, C.H. Kim, D.R. Kim, D.-H. Kim, E.K. Kim, H.Y. Kim, H.-R. Kim, J.-S. Kim, J.H. Kim, J.C. Kim, J.H. Kim, K.W. Kim, M.D. Kim, M.-M. Kim, P.K. Kim, S.W. Kim, S.-Y. Kim, Y.-S. Kim, Y. Kimchi, A. Kimmelman, A.C. Kimura, T. King, J.S. Kirkegaard, K. Kirkin, V. Kirshenbaum, L.A. Kishi, S. Kitajima, Y. Kitamoto, K. Kitaoka, Y. Kitazato, K. Kley, R.A. Klimecki, W.T. Klinkenberg, M. Klucken, J. Knævelsrud, H. Knecht, E. Knuppertz, L. Ko, J.-L. Kobayashi, S. Koch, J.C. Koechlin-Ramonatxo, C. Koenig, U. Koh, Y.H. Köhler, K. Kohlwein, S.D. Koike, M. Komatsu, M. Kominami, E. Kong, D. Kong, H.J. Konstantakou, E.G. Kopp, B.T. Korcsmaros, T. Korhonen, L. Korolchuk, V.I. Koshkina, N.V. Kou, Y. Koukourakis, M.I. Koumenis, C. Kovács, A.L. Kovács, T. Kovacs, W.J. Koya, D. Kraft, C. Krainc, D. Kramer, H. Kravic-Stevovic, T. Krek, W. Kretz-Remy, C. Krick, R. Krishnamurthy, M. Kriston-Vizi, J. Kroemer, G. Kruer, M.C. Kruger, R. Ktistakis, N.T. Kuchitsu, K. Kuhn, C. Kumar, A.P. Kumar, A. Kumar, A. Kumar, D. Kumar, D. Kumar, R. Kumar, S. Kundu, M. Kung, H.-J. Kuno, A. Kuo, S.-H. Kuret, J. Kurz, T. Kwok, T. Kwon, T.K. Kwon, Y.T. Kyrmizi, I. La Spada, A.R. Lafont, F. Lahm, T. Lakkaraju, A. Lam, T. Lamark, T. Lancel, S. Landowski, T.H. Lane, D.J.R. Lane, J.D. Lanzi, C. Lapaquette, P. Lapierre, L.R. Laporte, J. Laukkarinen, J. Laurie, G.W. Lavandero, S. Lavie, L. Lavoie, M.J. Law, B.Y.K. Law, H.K.-W. Law, K.B. Layfield, R. Lazo, P.A. Le Cam, L. Le Roch, K.G. Le Stunff, H. Leardkamolkarn, V. Lecuit, M. Lee, B.-H. Lee, C.-H. Lee, E.F. Lee, G.M. Lee, H.-J. Lee, H. Lee, J.K. Lee, J. Lee, J.-H. Lee, J.H. Lee, M. Lee, M.-S. Lee, P.J. Lee, S.W. Lee, S.-J. Lee, S.-J. Lee, S.Y. Lee, S.H. Lee, S.S. Lee, S.-J. Lee, S. Lee, Y.-R. Lee, Y.J. Lee, Y.H. Leeuwenburgh, C. Lefort, S. Legouis, R. Lei, J. Lei, Q.-Y. Leib, D.A. Leibowitz, G. Lekli, I. Lemaire, S.D. Lemasters, J.J. Lemberg, M.K. Lemoine, A. Leng, S. Lenz, G. Lenzi, P. Lerman, L.O. Barbato, D.L. Leu, J.I.J. Leung, H.Y. Levine, B. Lewis, P.A. Lezoualch, F. Li, C. Li, F. Li, F.-J. Li, J. Li, K. Li, L. Li, M. Li, Q. Li, R. Li, S. Li, W. Li, X. Li, Y. Lian, J. Liang, C. Liang, Q. Liao, Y. Liberal, J. Liberski, P.P. Lie, P. Lieberman, A.P. Lim, H.J. Lim, K.-L. Lim, K. Lima, R.T. Lin, C.-S. Lin, C.-F. Lin, F. Lin, F. Lin, F.-C. Lin, K. Lin, K.-H. Lin, P.-H. Lin, T. Lin, W.-W. Lin, Y.-S. Lin, Y. Linden, R. Lindholm, D. Lindqvist, L.M. Lingor, P. Linkermann, A. Liotta, L.A. Lipinski, M.M. Lira, V.A. Lisanti, M.P. Liton, P.B. Liu, B. Liu, C. Liu, C.-F. Liu, F. Liu, H.-J. Liu, J. Liu, J.-J. Liu, J.-L. Liu, K. Liu, L. Liu, L. Liu, Q. Liu, R.-Y. Liu, S. Liu, S. Liu, W. Liu, X.-D. Liu, X. Liu, X.-H. Liu, X. Liu, X. Liu, X. Liu, Y. Liu, Y. Liu, Z. Liu, Z. Liuzzi, J.P. Lizard, G. Ljujic, M. Lodhi, I.J. Logue, S.E. Lokeshwar, B.L. Long, Y.C. Lonial, S. Loos, B. López-Otín, C. López-Vicario, C. Lorente, M. Lorenzi, P.L. Lõrincz, P. Los, M. Lotze, M.T. Lovat, P.E. Lu, B. Lu, B. Lu, J. Lu, Q. Lu, S.-M. Lu, S. Lu, Y. Luciano, F. Luckhart, S. Lucocq, J.M. Ludovico, P. Lugea, A. Lukacs, N.W. Lum, J.J. Lund, A.H. Luo, H. Luo, J. Luo, S. Luparello, C. Lyons, T. Ma, J. Ma, Y. Ma, Y. Ma, Z. Machado, J. Machado-Santelli, G.M. Macian, F. MacIntosh, G.C. MacKeigan, J.P. Macleod, K.F. MacMicking, J.D. MacMillan-Crow, L.A. Madeo, F. Madesh, M. Madrigal-Matute, J. Maeda, A. Maeda, T. Maegawa, G. Maellaro, E. Maes, H. Magariños, M. Maiese, K. Maiti, T.K. Maiuri, L. Maiuri, M.C. Maki, C.G. Malli, R. Malorni, W. Maloyan, A. Mami-Chouaib, F. Man, N. Mancias, J.D. Mandelkow, E.-M. Mandell, M.A. Manfredi, A.A. Manié, S.N. Manzoni, C. Mao, K. Mao, Z. Mao, Z.-W. Marambaud, P. Marconi, A.M. Marelja, Z. Marfe, G. Margeta, M. Margittai, E. Mari, M. Mariani, F.V. Marin, C. Marinelli, S. Mariño, G. Markovic, I. Marquez, R. Martelli, A.M. Martens, S. Martin, K.R. Martin, S.J. Martin, S. Martin-Acebes, M.A. Martín-Sanz, P. Martinand-Mari, C. Martinet, W. Martinez, J. Martinez-Lopez, N. Martinez-Outschoorn, U. Martínez-Velázquez, M. Martinez-Vicente, M. Martins, W.K. Mashima, H. Mastrianni, J.A. Matarese, G. Matarrese, P. Mateo, R. Matoba, S. Matsumoto, N. Matsushita, T. Matsuura, A. Matsuzawa, T. Mattson, M.P. Matus, S. Maugeri, N. Mauvezin, C. Mayer, A. Maysinger, D. Mazzolini, G.D. McBrayer, M.K. McCall, K. McCormick, C. McInerney, G.M. McIver, S.C. McKenna, S. McMahon, J.J. McNeish, I.A. Mechta-Grigoriou, F. Medema, J.P. Medina, D.L. Megyeri, K. Mehrpour, M. Mehta, J.L. Mei, Y. Meier, U.-C. Meijer, A.J. Meléndez, A. Melino, G. Melino, S. de Melo, E.J.T. Mena, M.A. Meneghini, M.D. Menendez, J.A. Menezes, R. Meng, L. Meng, L.-H. Meng, S. Menghini, R. Menko, A.S. Menna-Barreto, R.F.S. Menon, M.B. Meraz-Ríos, M.A. Merla, G. Merlini, L. Merlot, A.M. Meryk, A. Meschini, S. Meyer, J.N. Mi, M.-T. Miao, C.-Y. Micale, L. Michaeli, S. Michiels, C. Migliaccio, A.R. Mihailidou, A.S. Mijaljica, D. Mikoshiba, K. Milan, E. Miller-Fleming, L. Mills, G.B. Mills, I.G. Minakaki, G. Minassian, B.A. Ming, X.-F. Minibayeva, F. Minina, E.A. Mintern, J.D. Minucci, S. Miranda-Vizuete, A. Mitchell, C.H. Miyamoto, S. Miyazawa, K. Mizushima, N. Mnich, K. Mograbi, B. Mohseni, S. Moita, L.F. Molinari, M. Molinari, M. Møller, A.B. Mollereau, B. Mollinedo, F. Mongillo, M. Monick, M.M. Montagnaro, S. Montell, C. Moore, D.J. Moore, M.N. Mora-Rodriguez, R. Moreira, P.I. Morel, E. Morelli, M.B. Moreno, S. Morgan, M.J. Moris, A. Moriyasu, Y. Morrison, J.L. Morrison, L.A. Morselli, E. Moscat, J. Moseley, P.L. Mostowy, S. Motori, E. Mottet, D. Mottram, J.C. Moussa, C.E.-H. Mpakou, V.E. Mukhtar, H. Levy, J.M.M. Muller, S. Muñoz-Moreno, R. Muñoz-Pinedo, C. Münz, C. Murphy, M.E. Murray, J.T. Murthy, A. Mysorekar, I.U. Nabi, I.R. Nabissi, M. Nader, G.A. Nagahara, Y. Nagai, Y. Nagata, K. Nagelkerke, A. Nagy, P. Naidu, S.R. Nair, S. Nakano, H. Nakatogawa, H. Nanjundan, M. Napolitano, G. Naqvi, N.I. Nardacci, R. Narendra, D.P. Narita, M. Nascimbeni, A.C. Natarajan, R. Navegantes, L.C. Nawrocki, S.T. Nazarko, T.Y. Nazarko, V.Y. Neill, T. Neri, L.M. Netea, M.G. Netea-Maier, R.T. Neves, B.M. Ney, P.A. Nezis, I.P. Nguyen, H.T.T. Nguyen, H.P. Nicot, A.-S. Nilsen, H. Nilsson, P. Nishimura, M. Nishino, I. Niso-Santano, M. Niu, H. Nixon, R.A. Njar, V.C.O. Noda, T. Noegel, A.A. Nolte, E.M. Norberg, E. Norga, K.K. Noureini, S.K. Notomi, S. Notterpek, L. Nowikovsky, K. Nukina, N. Nürnberger, T. O'donnell, V.B. O'donovan, T. O'dwyer, P.J. Oehme, I. Oeste, C.L. Ogawa, M. Ogretmen, B. Ogura, Y. Oh, Y.J. Ohmuraya, M. Ohshima, T. Ojha, R. Okamoto, K. Okazaki, T. Oliver, F.J. Ollinger, K. Olsson, S. Orban, D.P. Ordonez, P. Orhon, I. Orosz, L. O'rourke, E.J. Orozco, H. Ortega, A.L. Ortona, E. Osellame, L.D. Oshima, J. Oshima, S. Osiewacz, H.D. Otomo, T. Otsu, K. Ou, J.-H.J. Outeiro, T.F. Ouyang, D.-Y. Ouyang, H. Overholtzer, M. Ozbun, M.A. Ozdinler, P.H. Ozpolat, B. Pacelli, C. Paganetti, P. Page, G. Pages, G. Pagnini, U. Pajak, B. Pak, S.C. Pakos-Zebrucka, K. Pakpour, N. Palková, Z. Palladino, F. Pallauf, K. Pallet, N. Palmieri, M. Paludan, S.R. Palumbo, C. Palumbo, S. Pampliega, O. Pan, H. Pan, W. Panaretakis, T. Pandey, A. Pantazopoulou, A. Papackova, Z. Papademetrio, D.L. Papassideri, I. Papini, A. Parajuli, N. Pardo, J. Parekh, V.V. Parenti, G. Park, J.-I. Park, J. Park, O.K. Parker, R. Parlato, R. Parys, J.B. Parzych, K.R. Pasquet, J.-M. Pasquier, B. Pasumarthi, K.B.S. Patterson, C. Pattingre, S. Pattison, S. Pause, A. Pavenstädt, H. Pavone, F. Pedrozo, Z. Peña, F.J. Peñalva, M.A. Pende, M. Peng, J. Penna, F. Penninger, J.M. Pensalfini, A. Pepe, S. Pereira, G.J.S. Pereira, P.C. de la Cruz, V.P. Pérez-Pérez, M.E. Pérez-Rodríguez, D. Pérez-Sala, D. Perier, C. Perl, A. Perlmutter, D.H. Perrotta, I. Pervaiz, S. Pesonen, M. Pessin, J.E. Peters, G.J. Petersen, M. Petrache, I. Petrof, B.J. Petrovski, G. Phang, J.M. Piacentini, M. Pierdominici, M. Pierre, P. Pierrefite-Carle, V. Pietrocola, F. Pimentel-Muiños, F.X. Pinar, M. Pineda, B. Pinkas-Kramarski, R. Pinti, M. Pinton, P. Piperdi, B. Piret, J.M. Platanias, L.C. Platta, H.W. Plowey, E.D. Pöggeler, S. Poirot, M. Polčic, P. Poletti, A. Poon, A.H. Popelka, H. Popova, B. Poprawa, I. Poulose, S.M. Poulton, J. Powers, S.K. Powers, T. Pozuelo-Rubio, M. Prak, K. Prange, R. Prescott, M. Priault, M. Prince, S. Proia, R.L. Proikas-Cezanne, T. Prokisch, H. Promponas, V.J. Przyklenk, K. Puertollano, R. Pugazhenthi, S. Puglielli, L. Pujol, A. Puyal, J. Pyeon, D. Qi, X. Qian, W.-B. Qin, Z.-H. Qiu, Y. Qu, Z. Quadrilatero, J. Quinn, F. Raben, N. Rabinowich, H. Radogna, F. Ragusa, M.J. Rahmani, M. Raina, K. Ramanadham, S. Ramesh, R. Rami, A. Randall-Demllo, S. Randow, F. Rao, H. Rao, V.A. Rasmussen, B.B. Rasse, T.M. Ratovitski, E.A. Rautou, P.-E. Ray, S.K. Razani, B. Reed, B.H. Reggiori, F. Rehm, M. Reichert, A.S. Rein, T. Reiner, D.J. Reits, E. Ren, J. Ren, X. Renna, M. Reusch, J.E.B. Revuelta, J.L. Reyes, L. Rezaie, A.R. Richards, R.I. Richardson, R. Richetta, C. Riehle, M.A. Rihn, B.H. Rikihisa, Y. Riley, B.E. Rimbach, G. Rippo, M.R. Ritis, K. Rizzi, F. Rizzo, E. Roach, P.J. Robbins, J. Roberge, M. Roca, G. Roccheri, M.C. Rocha, S. Rodrigues, C.M.P. Rodríguez, C.I. de Cordoba, S.R. Rodriguez-Muela, N. Roelofs, J. Rogov, V.V. Rohn, T.T. Rohrer, B. Romanelli, D. Romani, L. Romano, P.S. Roncero, M.I.G. Rosa, J.L. Rosello, A. Rosen, K.V. Rosenstiel, P. Rost-Roszkowska, M. Roth, K.A. Roué, G. Rouis, M. Rouschop, K.M. Ruan, D.T. Ruano, D. Rubinsztein, D.C. Rucker, E.B., III Rudich, A. Rudolf, E. Rudolf, R. Ruegg, M.A. Ruiz-Roldan, C. Ruparelia, A.A. Rusmini, P. Russ, D.W. Russo, G.L. Russo, G. Russo, R. Rusten, T.E. Ryabovol, V. Ryan, K.M. Ryter, S.W. Sabatini, D.M. Sacher, M. Sachse, C. Sack, M.N. Sadoshima, J. Saftig, P. Sagi-Eisenberg, R. Sahni, S. Saikumar, P. Saito, T. Saitoh, T. Sakakura, K. Sakoh-Nakatogawa, M. Sakuraba, Y. Salazar-Roa, M. Salomoni, P. Saluja, A.K. Salvaterra, P.M. Salvioli, R. Samali, A. Sanchez, A.M.J. Sánchez-Alcázar, J.A. Sanchez-Prieto, R. Sandri, M. Sanjuan, M.A. Santaguida, S. Santambrogio, L. Santoni, G. Dos Santos, C.N. Saran, S. Sardiello, M. Sargent, G. Sarkar, P. Sarkar, S. Sarrias, M.R. Sarwal, M.M. Sasakawa, C. Sasaki, M. Sass, M. Sato, K. Sato, M. Satriano, J. Savaraj, N. Saveljeva, S. Schaefer, L. Schaible, U.E. Scharl, M. Schatzl, H.M. Schekman, R. Scheper, W. Schiavi, A. Schipper, H.M. Schmeisser, H. Schmidt, J. Schmitz, I. Schneider, B.E. Schneider, E.M. Schneider, J.L. Schon, E.A. Schönenberger, M.J. Schönthal, A.H. Schorderet, D.F. Schröder, B. Schuck, S. Schulze, R.J. Schwarten, M. Schwarz, T.L. Sciarretta, S. Scotto, K. Scovassi, A.I. Screaton, R.A. Screen, M. Seca, H. Sedej, S. Segatori, L. Segev, N. Seglen, P.O. Seguí-Simarro, J.M. Segura-Aguilar, J. Seiliez, I. Seki, E. Sell, C. Semenkovich, C.F. Semenza, G.L. Sen, U. Serra, A.L. Serrano-Puebla, A. Sesaki, H. Setoguchi, T. Settembre, C. Shacka, J.J. Shajahan-Haq, A.N. Shapiro, I.M. Sharma, S. She, H. Shen, C.-K.J. Shen, C.-C. Shen, H.-M. Shen, S. Shen, W. Sheng, R. Sheng, X. Sheng, Z.-H. Shepherd, T.G. Shi, J. Shi, Q. Shi, Q. Shi, Y. Shibutani, S. Shibuya, K. Shidoji, Y. Shieh, J.-J. Shih, C.-M. Shimada, Y. Shimizu, S. Shin, D.W. Shinohara, M.L. Shintani, M. Shintani, T. Shioi, T. Shirabe, K. Shiri-Sverdlov, R. Shirihai, O. Shore, G.C. Shu, C.-W. Shukla, D. Sibirny, A.A. Sica, V. Sigurdson, C.J. Sigurdsson, E.M. Sijwali, P.S. Sikorska, B. Silveira, W.A. Silvente-Poirot, S. Silverman, G.A. Simak, J. Simmet, T. Simon, A.K. Simon, H.-U. Simone, C. Simons, M. Simonsen, A. Singh, R. Singh, S.V. Singh, S.K. Sinha, D. Sinha, S. Sinicrope, F.A. Sirko, A. Sirohi, K. Sishi, B.J.N. Sittler, A. Siu, P.M. Sivridis, E. Skwarska, A. Slack, R. Slaninová, I. Slavov, N. Smaili, S.S. Smalley, K.S.M. Smith, D.R. Soenen, S.J. Soleimanpour, S.A. Solhaug, A. Somasundaram, K. Son, J.H. Sonawane, A. Song, C. Song, F. Song, H.K. Song, J.-X. Song, W. Soo, K.Y. Sood, A.K. Soong, T.W. Soontornniyomkij, V. Sorice, M. Sotgia, F. Soto-Pantoja, D.R. Sotthibundhu, A. Sousa, M.J. Spaink, H.P. Span, P.N. Spang, A. Sparks, J.D. Speck, P.G. Spector, S.A. Spies, C.D. Springer, W. Clair, D.S. Stacchiotti, A. Staels, B. Stang, M.T. Starczynowski, D.T. Starokadomskyy, P. Steegborn, C. Steele, J.W. Stefanis, L. Steffan, J. Stellrecht, C.M. Stenmark, H. Stepkowski, T.M. Stern, S.T. Stevens, C. Stockwell, B.R. Stoka, V. Storchova, Z. Stork, B. Stratoulias, V. Stravopodis, D.J. Strnad, P. Strohecker, A.M. Ström, A.-L. Stromhaug, P. Stulik, J. Su, Y.-X. Su, Z. Subauste, C.S. Subramaniam, S. Sue, C.M. Suh, S.W. Sui, X. Sukseree, S. Sulzer, D. Sun, F.-L. Sun, J. Sun, J. Sun, S.-Y. Sun, Y. Sun, Y. Sun, Y. Sundaramoorthy, V. Sung, J. Suzuki, H. Suzuki, K. Suzuki, N. Suzuki, T. Suzuki, Y.J. Swanson, M.S. Swanton, C. Swärd, K. Swarup, G. Sweeney, S.T. Sylvester, P.W. Szatmari, Z. Szegezdi, E. Szlosarek, P.W. Taegtmeyer, H. Tafani, M. Taillebourg, E. Tait, S.W.G. Takacs-Vellai, K. Takahashi, Y. Takáts, S. Takemura, G. Takigawa, N. Talbot, N.J. Tamagno, E. Tamburini, J. Tan, C.-P. Tan, L. Tan, M.L. Tan, M. Tan, Y.-J. Tanaka, K. Tanaka, M. Tang, D. Tang, D. Tang, G. Tanida, I. Tanji, K. Tannous, B.A. Tapia, J.A. Tasset-Cuevas, I. Tatar, M. Tavassoly, I. Tavernarakis, N. Taylor, A. Taylor, G.S. Taylor, G.A. Taylor, J.P. Taylor, M.J. Tchetina, E.V. Tee, A.R. Teixeira-Clerc, F. Telang, S. Tencomnao, T. Teng, B.-B. Teng, R.-J. Terro, F. Tettamanti, G. Theiss, A.L. Theron, A.E. Thomas, K.J. Thomé, M.P. Thomes, P.G. Thorburn, A. Thorner, J. Thum, T. Thumm, M. Thurston, T.L.M. Tian, L. Till, A. Ting, J.P.-Y. Ting, J.P.Y. Titorenko, V.I. Toker, L. Toldo, S. Tooze, S.A. Topisirovic, I. Torgersen, M.L. Torosantucci, L. Torriglia, A. Torrisi, M.R. Tournier, C. Towns, R. Trajkovic, V. Travassos, L.H. Triola, G. Tripathi, D.N. Trisciuoglio, D. Troncoso, R. Trougakos, I.P. Truttmann, A.C. Tsai, K.-J. Tschan, M.P. Tseng, Y.-H. Tsukuba, T. Tsung, A. Tsvetkov, A.S. Tu, S. Tuan, H.-Y. Tucci, M. Tumbarello, D.A. Turk, B. Turk, V. Turner, R.F.B. Tveita, A.A. Tyagi, S.C. Ubukata, M. Uchiyama, Y. Udelnow, A. Ueno, T. Umekawa, M. Umemiya-Shirafuji, R. Underwood, B.R. Ungermann, C. Ureshino, R.P. Ushioda, R. Uversky, V.N. Uzcátegui, N.L. Vaccari, T. Vaccaro, M.I. Váchová, L. Vakifahmetoglu-Norberg, H. Valdor, R. Valente, E.M. Vallette, F. Valverde, A.M. Van den Berghe, G. Van Den Bosch, L. van den Brink, G.R. van der Goot, F.G. van der Klei, I.J. van der Laan, L.J.W. van Doorn, W.G. van Egmond, M. van Golen, K.L. Van Kaer, L. Campagne, M.L. Vandenabeele, P. Vandenberghe, W. Vanhorebeek, I. Varela-Nieto, I. Vasconcelos, M.H. Vasko, R. Vavvas, D.G. Vega-Naredo, I. Velasco, G. Velentzas, A.D. Velentzas, P.D. Vellai, T. Vellenga, E. Vendelbo, M.H. Venkatachalam, K. Ventura, N. Ventura, S. Veras, P.S.T. Verdier, M. Vertessy, B.G. Viale, A. Vidal, M. Vieira, H.L.A. Vierstra, R.D. Vigneswaran, N. Vij, N. Vila, M. Villar, M. Villar, V.H. Villarroya, J. Vindis, C. Viola, G. Viscomi, M.T. Vitale, G. Vogl, D.T. Voitsekhovskaja, O.V. von Haefen, C. von Schwarzenberg, K. Voth, D.E. Vouret-Craviari, V. Vuori, K. Vyas, J.M. Waeber, C. Walker, C.L. Walker, M.J. Walter, J. Wan, L. Wan, X. Wang, B. Wang, C. Wang, C.-Y. Wang, C. Wang, C. Wang, C. Wang, D. Wang, F. Wang, F. Wang, G. Wang, H.-J. Wang, H. Wang, H.-G. Wang, H. Wang, H.-D. Wang, J. Wang, J. Wang, M. Wang, M.-Q. Wang, P.-Y. Wang, P. Wang, R.C. Wang, S. Wang, T.-F. Wang, X. Wang, X.-J. Wang, X.-W. Wang, X. Wang, X. Wang, Y. Wang, Y. Wang, Y. Wang, Y.-J. Wang, Y. Wang, Y. Wang, Y.T. Wang, Y. Wang, Z.-N. Wappner, P. Ward, C. Ward, D.M.V. Warnes, G. Watada, H. Watanabe, Y. Watase, K. Weaver, T.E. Weekes, C.D. Wei, J. Weide, T. Weihl, C.C. Weindl, G. Weis, S.N. Wen, L. Wen, X. Wen, Y. Westermann, B. Weyand, C.M. White, A.R. White, E. Whitton, J.L. Whitworth, A.J. Wiels, J. Wild, F. Wildenberg, M.E. Wileman, T. Wilkinson, D.S. Wilkinson, S. Willbold, D. Williams, C. Williams, K. Williamson, P.R. Winklhofer, K.F. Witkin, S.S. Wohlgemuth, S.E. Wollert, T. Wolvetang, E.J. Wong, E. Wong, G.W. Wong, R.W. Wong, V.K.W. Woodcock, E.A. Wright, K.L. Wu, C. Wu, D. Wu, G.S. Wu, J. Wu, J. Wu, M. Wu, M. Wu, S. Wu, W.K.K. Wu, Y. Wu, Z. Xavier, C.P.R. Xavier, R.J. Xia, G.-X. Xia, T. Xia, W. Xia, Y. Xiao, H. Xiao, J. Xiao, S. Xiao, W. Xie, C.-M. Xie, Z. Xie, Z. Xilouri, M. Xiong, Y. Xu, C. Xu, C. Xu, F. Xu, H. Xu, H. Xu, J. Xu, J. Xu, J. Xu, L. Xu, X. Xu, Y. Xu, Y. Xu, Z.-X. Xu, Z. Xue, Y. Yamada, T. Yamamoto, A. Yamanaka, K. Yamashina, S. Yamashiro, S. Yan, B. Yan, B. Yan, X. Yan, Z. Yanagi, Y. Yang, D.-S. Yang, J.-M. Yang, L. Yang, M. Yang, P.-M. Yang, P. Yang, Q. Yang, W. Yang, W.Y. Yang, X. Yang, Y. Yang, Y. Yang, Z. Yang, Z. Yao, M.-C. Yao, P.J. Yao, X. Yao, Z. Yao, Z. Yasui, L.S. Ye, M. Yedvobnick, B. Yeganeh, B. Yeh, E.S. Yeyati, P.L. Yi, F. Yi, L. Yin, X.-M. Yip, C.K. Yoo, Y.-M. Yoo, Y.H. Yoon, S.-Y. Yoshida, K.-I. Yoshimori, T. Young, K.H. Yu, H. Yu, J.J. Yu, J.-T. Yu, J. Yu, L. Yu, W.H. Yu, X.-F. Yu, Z. Yuan, J. Yuan, Z.-M. Yue, B.Y.J.T. Yue, J. Yue, Z. Zacks, D.N. Zacksenhaus, E. Zaffaroni, N. Zaglia, T. Zakeri, Z. Zecchini, V. Zeng, J. Zeng, M. Zeng, Q. Zervos, A.S. Zhang, D.D. Zhang, F. Zhang, G. Zhang, G.-C. Zhang, H. Zhang, H. Zhang, H. Zhang, J. Zhang, J. Zhang, J. Zhang, J.-P. Zhang, L. Zhang, L. Zhang, L. Zhang, M.-Y. Zhang, X. Zhang, X.D. Zhang, Y. Zhang, Y. Zhang, Y. Zhang, Y. Zhang, Y. Zhao, M. Zhao, W.-L. Zhao, X. Zhao, Y.G. Zhao, Y. Zhao, Y. Zhao, Y.-X. Zhao, Z. Zhao, Z.J. Zheng, D. Zheng, X.-L. Zheng, X. Zhivotovsky, B. Zhong, Q. Zhou, G.-Z. Zhou, G. Zhou, H. Zhou, S.-F. Zhou, X.-J. Zhu, H. Zhu, H. Zhu, W.-G. Zhu, W. Zhu, X.-F. Zhu, Y. Zhuang, S.-M. Zhuang, X. Ziparo, E. Zois, C.E. Zoladek, T. Zong, W.-X. Zorzano, A. Zughaier, S.M.

Published
2016

50. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)

Author

Klionsky, D.J. Abdelmohsen, K. Abe, A. Abedin, M.J. Abeliovich, H. Arozena, A.A. Adachi, H. Adams, C.M. Adams, P.D. Adeli, K. Adhihetty, P.J. Adler, S.G. Agam, G. Agarwal, R. Aghi, M.K. Agnello, M. Agostinis, P. Aguilar, P.V. Aguirre-Ghiso, J. Airoldi, E.M. Ait-Si-Ali, S. Akematsu, T. Akporiaye, E.T. Al-Rubeai, M. Albaiceta, G.M. Albanese, C. Albani, D. Albert, M.L. Aldudo, J. Algül, H. Alirezaei, M. Alloza, I. Almasan, A. Almonte-Beceril, M. Alnemri, E.S. Alonso, C. Altan-Bonnet, N. Altieri, D.C. Alvarez, S. Alvarez-Erviti, L. Alves, S. Amadoro, G. Amano, A. Amantini, C. Ambrosio, S. Amelio, I. Amer, A.O. Amessou, M. Amon, A. An, Z. Anania, F.A. Andersen, S.U. Andley, U.P. Andreadi, C.K. Andrieu-Abadie, N. Anel, A. Ann, D.K. Anoopkumar-Dukie, S. Antonioli, M. Aoki, H. Apostolova, N. Aquila, S. Aquilano, K. Araki, K. Arama, E. Aranda, A. Araya, J. Arcaro, A. Arias, E. Arimoto, H. Ariosa, A.R. Armstrong, J.L. Arnould, T. Arsov, I. Asanuma, K. Askanas, V. Asselin, E. Atarashi, R. Atherton, S.S. Atkin, J.D. Attardi, L.D. Auberger, P. Auburger, G. Aurelian, L. Autelli, R. Avagliano, L. Avantaggiati, M.L. Avrahami, L. Azad, N. Awale, S. Bachetti, T. Backer, J.M. Bae, D.-H. Bae, J.-S. Bae, O.-N. Bae, S.H. Baehrecke, E.H. Baek, S.-H. Baghdiguian, S. Bagniewska-Zadworna, A. Bai, H. Bai, J. Bai, X.-Y. Bailly, Y. Balaji, K.N. Balduini, W. Ballabio, A. Balzan, R. Banerjee, R. Bánhegyi, G. Bao, H. Barbeau, B. Barrachina, M.D. Barreiro, E. Bartel, B. Bartolomé, A. Bassham, D.C. Bassi, M.T. Bast, R.C., Jr. Basu, A. Batista, M.T. Batoko, H. Battino, M. Bauckman, K. Baumgarner, B.L. Bayer, K.U. Beale, R. Beaulieu, J.-F. Beck, G.R., Jr. Becker, C. Beckham, J.D. Bédard, P.-A. Bednarski, P.J. Begley, T.J. Behl, C. Behrends, C. Behrens, G.M.N. Behrns, K.E. Bejarano, E. Belaid, A. Belleudi, F. Bénard, G. Berchem, G. Bergamaschi, D. Bergami, M. Berkhout, B. Berliocchi, L. Bernard, A. Bernard, M. Bernassola, F. Bertolotti, A. Bess, A.S. Besteiro, S. Bettuzzi, S. Bhalla, S. Bhattacharyya, S. Bhutia, S.K. Biagosch, C. Bianchi, M.W. Biard-Piechaczyk, M. Billes, V. Bincoletto, C. Bingol, B. Bird, S.W. Bitoun, M. Bjedov, I. Blackstone, C. Blanc, L. Blanco, G.A. Blomhoff, H.K. Boada-Romero, E. Böckler, S. Boes, M. Boesze-Battaglia, K. Boise, L.H. Bolino, A. Boman, A. Bonaldo, P. Bordi, M. Bosch, J. Botana, L.M. Botti, J. Bou, G. Bouché, M. Bouchecareilh, M. Boucher, M.-J. Boulton, M.E. Bouret, S.G. Boya, P. Boyer-Guittaut, M. Bozhkov, P.V. Brady, N. Braga, V.M.M. Brancolini, C. Braus, G.H. Bravo-San-Pedro, J.M. Brennan, L.A. Bresnick, E.H. Brest, P. Bridges, D. Bringer, M.-A. Brini, M. Brito, G.C. Brodin, B. Brookes, P.S. Brown, E.J. Brown, K. Broxmeyer, H.E. Bruhat, A. Brum, P.C. Brumell, J.H. Brunetti-Pierri, N. Bryson-Richardson, R.J. Buch, S. Buchan, A.M. Budak, H. Bulavin, D.V. Bultman, S.J. Bultynck, G. Bumbasirevic, V. Burelle, Y. Burke, R.E. Burmeister, M. Bütikofer, P. Caberlotto, L. Cadwell, K. Cahova, M. Cai, D. Cai, J. Cai, Q. Calatayud, S. Camougrand, N. Campanella, M. Campbell, G.R. Campbell, M. Campello, S. Candau, R. Caniggia, I. Cantoni, L. Cao, L. Caplan, A.B. Caraglia, M. Cardinali, C. Cardoso, S.M. Carew, J.S. Carleton, L.A. Carlin, C.R. Carloni, S. Carlsson, S.R. Carmona-Gutierrez, D. Carneiro, L.A.M. Carnevali, O. Carra, S. Carrier, A. Carroll, B. Casas, C. Casas, J. Cassinelli, G. Castets, P. Castro-Obregon, S. Cavallini, G. Ceccherini, I. Cecconi, F. Cederbaum, A.I. Ceña, V. Cenci, S. Cerella, C. Cervia, D. Cetrullo, S. Chaachouay, H. Chae, H.-J. Chagin, A.S. Chai, C.-Y. Chakrabarti, G. Chamilos, G. Chan, E.Y.W. Chan, M.T.V. Chandra, D. Chandra, P. Chang, C.-P. Chang, R.C.-C. Chang, T.Y. Chatham, J.C. Chatterjee, S. Chauhan, S. Che, Y. Cheetham, M.E. Cheluvappa, R. Chen, C.-J. Chen, G. Chen, G.-C. Chen, G. Chen, H. Chen, J.W. Chen, J.-K. Chen, M. Chen, M. Chen, P. Chen, Q. Chen, Q. Chen, S.-D. Chen, S. Chen, S.S.-L. Chen, W. Chen, W.-J. Chen, W.Q. Chen, W. Chen, X. Chen, Y.-H. Chen, Y.-G. Chen, Y. Chen, Y. Chen, Y. Chen, Y.-J. Chen, Y.-Q. Chen, Y. Chen, Z. Chen, Z. Cheng, A. Cheng, C.H.K. Cheng, H. Cheong, H. Cherry, S. Chesney, J. Cheung, C.H.A. Chevet, E. Chi, H.C. Chi, S.-G. Chiacchiera, F. Chiang, H.-L. Chiarelli, R. Chiariello, M. Chieppa, M. Chin, L.-S. Chiong, M. Chiu, G.N.C. Cho, D.-H. Cho, S.-G. Cho, W.C. Cho, Y.-Y. Cho, Y.-S. Choi, A.M.K. Choi, E.-J. Choi, E.-K. Choi, J. Choi, M.E. Choi, S.-I. Chou, T.-F. Chouaib, S. Choubey, D. Choubey, V. Chow, K.-C. Chowdhury, K. Chu, C.T. Chuang, T.-H. Chun, T. Chung, H. Chung, T. Chung, Y.-L. Chwae, Y.-J. Cianfanelli, V. Ciarcia, R. Ciechomska, I.A. Ciriolo, M.R. Cirone, M. Claerhout, S. Clague, M.J. Clària, J. Clarke, P.G.H. Clarke, R. Clementi, E. Cleyrat, C. Cnop, M. Coccia, E.M. Cocco, T. Codogno, P. Coers, J. Cohen, E.E.W. Colecchia, D. Coletto, L. Coll, N.S. Colucci-Guyon, E. Comincini, S. Condello, M. Cook, K.L. Coombs, G.H. Cooper, C.D. Cooper, J.M. Coppens, I. Corasaniti, M.T. Corazzari, M. Corbalan, R. Corcelle-Termeau, E. Cordero, M.D. Corral-Ramos, C. Corti, O. Cossarizza, A. Costelli, P. Costes, S. Cotman, S.L. Coto-Montes, A. Cottet, S. Couve, E. Covey, L.R. Cowart, L.A. Cox, J.S. Coxon, F.P. Coyne, C.B. Cragg, M.S. Craven, R.J. Crepaldi, T. Crespo, J.L. Criollo, A. Crippa, V. Cruz, M.T. Cuervo, A.M. Cuezva, J.M. Cui, T. Cutillas, P.R. Czaja, M.J. Czyzyk-Krzeska, M.F. Dagda, R.K. Dahmen, U. Dai, C. Dai, W. Dai, Y. Dalby, K.N. Valle, L.D. Dalmasso, G. D'amelio, M. Damme, M. Darfeuille-Michaud, A. Dargemont, C. Darley-Usmar, V.M. Dasarathy, S. Dasgupta, B. Dash, S. Dass, C.R. Davey, H.M. Davids, L.M. Dávila, D. Davis, R.J. Dawson, T.M. Dawson, V.L. Daza, P. de Belleroche, J. de Figueiredo, P. de Figueiredo, R.C.B.Q. de la Fuente, J. De Martino, L. De Matteis, A. De Meyer, G.R.Y. De Milito, A. De Santi, M. de Souza, W. De Tata, V. De Zio, D. Debnath, J. Dechant, R. Decuypere, J.-P. Deegan, S. Dehay, B. Del Bello, B. Del Re, D.P. Delage-Mourroux, R. Delbridge, L.M.D. Deldicque, L. Delorme-Axford, E. Deng, Y. Dengjel, J. Denizot, M. Dent, P. Der, C.J. Deretic, V. Derrien, B. Deutsch, E. Devarenne, T.P. Devenish, R.J. Di Bartolomeo, S. Di Daniele, N. Di Domenico, F. Di Nardo, A. Di Paola, S. Di Pietro, A. Di Renzo, L. Di Antonio, A. Díaz-Araya, G. Díaz-Laviada, I. Diaz-Meco, M.T. Diaz-Nido, J. Dickey, C.A. Dickson, R.C. Diederich, M. Digard, P. Dikic, I. Dinesh-Kumar, S.P. Ding, C. Ding, W.-X. Ding, Z. Dini, L. Distler, J.H.W. Diwan, A. Djavaheri-Mergny, M. Dmytruk, K. Dobson, R.C.J. Doetsch, V. Dokladny, K. Dokudovskaya, S. Donadelli, M. Dong, X.C. Dong, X. Dong, Z. Donohue, T.M., Jr. Donohue-Jr, T.M. Doran, K.S. D'orazi, G. Dorn, G.W., II Dosenko, V. Dridi, S. Drucker, L. Du, J. Du, L.-L. Du, L. du Toit, A. Dua, P. Duan, L. Duann, P. Dubey, V.K. Duchen, M.R. Duchosal, M.A. Duez, H. Dugail, I. Dumit, V.I. Duncan, M.C. Dunlop, E.A. Dunn, W.A., Jr. Dupont, N. Dupuis, L. Durán, R.V. Durcan, T.M. Duvezin-Caubet, S. Duvvuri, U. Eapen, V. Ebrahimi-Fakhari, D. Echard, A. Eckhart, L. Edelstein, C.L. Edinger, A.L. Eichinger, L. Eisenberg, T. Eisenberg-Lerner, A. Eissa, N.T. El-Deiry, W.S. El-Khoury, V. Elazar, Z. Eldar-Finkelman, H. Elliott, C.J.H. Emanuele, E. Emmenegger, U. Engedal, N. Engelbrecht, A.-M. Engelender, S. Enserink, J.M. Erdmann, R. Erenpreisa, J. Eri, R. Eriksen, J.L. Erman, A. Escalante, R. Eskelinen, E.-L. Espert, L. Esteban-Martínez, L. Evans, T.J. Fabri, M. Fabrias, G. Fabrizi, C. Facchiano, A. Færgeman, N.J. Faggioni, A. Fairlie, W.D. Fan, C. Fan, D. Fan, J. Fang, S. Fanto, M. Fanzani, A. Farkas, T. Faure, M. Favier, F.B. Fearnhead, H. Federici, M. Fei, E. Felizardo, T.C. Feng, H. Feng, Y. Feng, Y. Ferguson, T.A. Fernández, Á.F. Fernandez-Barrena, M.G. Fernandez-Checa, J.C. Fernández-López, A. Fernandez-Zapico, M.E. Feron, O. Ferraro, E. Ferreira-Halder, C.V. Fesus, L. Feuer, R. Fiesel, F.C. Filippi-Chiela, E.C. Filomeni, G. Fimia, G.M. Fingert, J.H. Finkbeiner, S. Finkel, T. Fiorito, F. Fisher, P.B. Flajolet, M. Flamigni, F. Florey, O. Florio, S. Floto, R.A. Folini, M. Follo, C. Fon, E.A. Fornai, F. Fortunato, F. Fraldi, A. Franco, R. Francois, A. François, A. Frankel, L.B. Fraser, I.D.C. Frey, N. Freyssenet, D.G. Frezza, C. Friedman, S.L. Frigo, D.E. Fu, D. Fuentes, J.M. Fueyo, J. Fujitani, Y. Fujiwara, Y. Fujiya, M. Fukuda, M. Fulda, S. Fusco, C. Gabryel, B. Gaestel, M. Gailly, P. Gajewska, M. Galadari, S. Galili, G. Galindo, I. Galindo, M.F. Galliciotti, G. Galluzzi, L. Galluzzi, L. Galy, V. Gammoh, N. Gandy, S. Ganesan, A.K. Ganesan, S. Ganley, I.G. Gannagé, M. Gao, F.-B. Gao, F. Gao, J.-X. Nannig, L.G. Véscovi, E.G. Garcia-Macía, M. Garcia-Ruiz, C. Garg, A.D. Garg, P.K. Gargini, R. Gassen, N.C. Gatica, D. Gatti, E. Gavard, J. Gavathiotis, E. Ge, L. Ge, P. Ge, S. Gean, P.-W. Gelmetti, V. Genazzani, A.A. Geng, J. Genschik, P. Gerner, L. Gestwicki, J.E. Gewirtz, D.A. Ghavami, S. Ghigo, E. Ghosh, D. Giammarioli, A.M. Giampieri, F. Giampietri, C. Giatromanolaki, A. Gibbings, D.J. Gibellini, L. Gibson, S.B. Ginet, V. Giordano, A. Giorgini, F. Giovannetti, E. Girardin, S.E. Gispert, S. Giuliano, S. Gladson, C.L. Glavic, A. Gleave, M. Godefroy, N. Gogal, R.M., Jr. Gokulan, K. Goldman, G.H. Goletti, D. Goligorsky, M.S. Gomes, A.V. Gomes, L.C. Gomez, H. Gomez-Manzano, C. Gómez-Sánchez, R. Gonçalves, D.A.P. Goncu, E. Gong, Q. Gongora, C. Gonzalez, C.B. Gonzalez-Alegre, P. Gonzalez-Cabo, P. González-Polo, R.A. Goping, I.S. Gorbea, C. Gorbunov, N.V. Goring, D.R. Gorman, A.M. Gorski, S.M. Goruppi, S. Goto-Yamada, S. Gotor, C. Gottlieb, R.A. Gozes, I. Gozuacik, D. Graba, Y. Graef, M. Granato, G.E. Grant, G.D. Grant, S. Gravina, G.L. Green, D.R. Greenhough, A. Greenwood, M.T. Grimaldi, B. Gros, F. Grose, C. Groulx, J.-F. Gruber, F. Grumati, P. Grune, T. Guan, J.-L. Guan, K.-L. Guerra, B. Guillen, C. Gulshan, K. Gunst, J. Guo, C. Guo, L. Guo, M. Guo, W. Guo, X.-G. Gust, A.A. Gustafsson, Å.B. Gutierrez, E. Gutierrez, M.G. Gwak, H.-S. Haas, A. Haber, J.E. Hadano, S. Hagedorn, M. Hahn, D.R. Halayko, A.J. Hamacher-Brady, A. Hamada, K. Hamai, A. Hamann, A. Hamasaki, M. Hamer, I. Hamid, Q. Hammond, E.M. Han, F. Han, W. Handa, J.T. Hanover, J.A. Hansen, M. Harada, M. Harhaji-Trajkovic, L. Harper, J.W. Harrath, A.H. Harris, A.L. Harris, J. Hasler, U. Hasselblatt, P. Hasui, K. Hawley, R.G. Hawley, T.S. He, C. He, C.Y. He, F. He, G. He, R.-R. He, X.-H. He, Y.-W. He, Y.-Y. Heath, J.K. Hébert, M.-J. Heinzen, R.A. Helgason, G.V. Hensel, M. Henske, E.P. Her, C. Herman, P.K. Hernández, A. Hernandez, C. Hernández-Tiedra, S. Hetz, C. Hiesinger, P.R. Higaki, K. Hilfiker, S. Hill, B.G. Hill, J.A. Hill, W.D. Hino, K. Hofius, D. Hofman, P. Höglinger, G.U. Höhfeld, J. Holz, M.K. Hong, Y. Hood, D.A. Hoozemans, J.J.M. Hoppe, T. Hsu, C. Hsu, C.-Y. Hsu, L.-C. Hu, D. Hu, G. Hu, H.-M. Hu, H. Hu, M.C. Hu, Y.-C. Hu, Z.-W. Hua, F. Hua, Y. Huang, C. Huang, H.-L. Huang, K.-H. Huang, K.-Y. Huang, S. Huang, S. Huang, W.-P. Huang, Y.-R. Huang, Y. Huang, Y. Huber, T.B. Huebbe, P. Huh, W.-K. Hulmi, J.J. Hur, G.M. Hurley, J.H. Husak, Z. Hussain, S.N.A. Hussain, S. Hwang, J.J. Hwang, S. Hwang, T.I.S. Ichihara, A. Imai, Y. Imbriano, C. Inomata, M. Into, T. Iovane, V. Iovanna, J.L. Iozzo, R.V. Ip, N.Y. Irazoqui, J.E. Iribarren, P. Isaka, Y. Isakovic, A.J. Ischiropoulos, H. Isenberg, J.S. Ishaq, M. Ishida, H. Ishii, I. Ishmael, J.E. Isidoro, C. Isobe, K.-I. Isono, E. Issazadeh-Navikas, S. Itahana, K. Itakura, E. Ivanov, A.I. Iyer, A.K.V. Izquierdo, J.M. Izumi, Y. Izzo, V. Jäättelä, M. Jaber, N. Jackson, D.J. Jackson, W.T. Jacob, T.G. Jacques, T.S. Jagannath, C. Jain, A. Jana, N.R. Jang, B.K. Jani, A. Janji, B. Jannig, P.R. Jansson, P.J. Jean, S. Jendrach, M. Jeon, J.-H. Jessen, N. Jeung, E.-B. Jia, K. Jia, L. Jiang, H. Jiang, H. Jiang, L. Jiang, T. Jiang, X. Jiang, X. Jiang, Y. Jiang, Y. Jiménez, A. Jin, C. Jin, H. Jin, L. Jin, M. Jin, S. Jinwal, U.K. Jo, E.-K. Johansen, T. Johnson, D.E. Johnson, G.V.W. Johnson, J.D. Jonasch, E. Jones, C. Joosten, L.A.B. Jordan, J. Joseph, A.-M. Joseph, B. Joubert, A.M. Ju, D. Ju, J. Juan, H.-F. Juenemann, K. Juhász, G. Jung, H.S. Jung, J.U. Jung, Y.-K. Jungbluth, H. Justice, M.J. Jutten, B. Kaakoush, N.O. Kaarniranta, K. Kaasik, A. Kabuta, T. Kaeffer, B. Kågedal, K. Kahana, A. Kajimura, S. Kakhlon, O. Kalia, M. Kalvakolanu, D.V. Kamada, Y. Kambas, K. Kaminskyy, V.O. Kampinga, H.H. Kandouz, M. Kang, C. Kang, R. Kang, T.-C. Kanki, T. Kanneganti, T.-D. Kanno, H. Kanthasamy, A.G. Kantorow, M. Kaparakis-Liaskos, M. Kapuy, O. Karantza, V. Karim, M.R. Karmakar, P. Kaser, A. Kaushik, S. Kawula, T. Kaynar, A.M. Ke, P.-Y. Ke, Z.-J. Kehrl, J.H. Keller, K.E. Kemper, J.K. Kenworthy, A.K. Kepp, O. Kern, A. Kesari, S. Kessel, D. Ketteler, R. Kettelhut, I.C. Khambu, B. Khan, M.M. Khandelwal, V.K.M. Khare, S. Kiang, J.G. Kiger, A.A. Kihara, A. Kim, A.L. Kim, C.H. Kim, D.R. Kim, D.-H. Kim, E.K. Kim, H.Y. Kim, H.-R. Kim, J.-S. Kim, J.H. Kim, J.C. Kim, J.H. Kim, K.W. Kim, M.D. Kim, M.-M. Kim, P.K. Kim, S.W. Kim, S.-Y. Kim, Y.-S. Kim, Y. Kimchi, A. Kimmelman, A.C. Kimura, T. King, J.S. Kirkegaard, K. Kirkin, V. Kirshenbaum, L.A. Kishi, S. Kitajima, Y. Kitamoto, K. Kitaoka, Y. Kitazato, K. Kley, R.A. Klimecki, W.T. Klinkenberg, M. Klucken, J. Knævelsrud, H. Knecht, E. Knuppertz, L. Ko, J.-L. Kobayashi, S. Koch, J.C. Koechlin-Ramonatxo, C. Koenig, U. Koh, Y.H. Köhler, K. Kohlwein, S.D. Koike, M. Komatsu, M. Kominami, E. Kong, D. Kong, H.J. Konstantakou, E.G. Kopp, B.T. Korcsmaros, T. Korhonen, L. Korolchuk, V.I. Koshkina, N.V. Kou, Y. Koukourakis, M.I. Koumenis, C. Kovács, A.L. Kovács, T. Kovacs, W.J. Koya, D. Kraft, C. Krainc, D. Kramer, H. Kravic-Stevovic, T. Krek, W. Kretz-Remy, C. Krick, R. Krishnamurthy, M. Kriston-Vizi, J. Kroemer, G. Kruer, M.C. Kruger, R. Ktistakis, N.T. Kuchitsu, K. Kuhn, C. Kumar, A.P. Kumar, A. Kumar, A. Kumar, D. Kumar, D. Kumar, R. Kumar, S. Kundu, M. Kung, H.-J. Kuno, A. Kuo, S.-H. Kuret, J. Kurz, T. Kwok, T. Kwon, T.K. Kwon, Y.T. Kyrmizi, I. La Spada, A.R. Lafont, F. Lahm, T. Lakkaraju, A. Lam, T. Lamark, T. Lancel, S. Landowski, T.H. Lane, D.J.R. Lane, J.D. Lanzi, C. Lapaquette, P. Lapierre, L.R. Laporte, J. Laukkarinen, J. Laurie, G.W. Lavandero, S. Lavie, L. Lavoie, M.J. Law, B.Y.K. Law, H.K.-W. Law, K.B. Layfield, R. Lazo, P.A. Le Cam, L. Le Roch, K.G. Le Stunff, H. Leardkamolkarn, V. Lecuit, M. Lee, B.-H. Lee, C.-H. Lee, E.F. Lee, G.M. Lee, H.-J. Lee, H. Lee, J.K. Lee, J. Lee, J.-H. Lee, J.H. Lee, M. Lee, M.-S. Lee, P.J. Lee, S.W. Lee, S.-J. Lee, S.-J. Lee, S.Y. Lee, S.H. Lee, S.S. Lee, S.-J. Lee, S. Lee, Y.-R. Lee, Y.J. Lee, Y.H. Leeuwenburgh, C. Lefort, S. Legouis, R. Lei, J. Lei, Q.-Y. Leib, D.A. Leibowitz, G. Lekli, I. Lemaire, S.D. Lemasters, J.J. Lemberg, M.K. Lemoine, A. Leng, S. Lenz, G. Lenzi, P. Lerman, L.O. Barbato, D.L. Leu, J.I.J. Leung, H.Y. Levine, B. Lewis, P.A. Lezoualch, F. Li, C. Li, F. Li, F.-J. Li, J. Li, K. Li, L. Li, M. Li, Q. Li, R. Li, S. Li, W. Li, X. Li, Y. Lian, J. Liang, C. Liang, Q. Liao, Y. Liberal, J. Liberski, P.P. Lie, P. Lieberman, A.P. Lim, H.J. Lim, K.-L. Lim, K. Lima, R.T. Lin, C.-S. Lin, C.-F. Lin, F. Lin, F. Lin, F.-C. Lin, K. Lin, K.-H. Lin, P.-H. Lin, T. Lin, W.-W. Lin, Y.-S. Lin, Y. Linden, R. Lindholm, D. Lindqvist, L.M. Lingor, P. Linkermann, A. Liotta, L.A. Lipinski, M.M. Lira, V.A. Lisanti, M.P. Liton, P.B. Liu, B. Liu, C. Liu, C.-F. Liu, F. Liu, H.-J. Liu, J. Liu, J.-J. Liu, J.-L. Liu, K. Liu, L. Liu, L. Liu, Q. Liu, R.-Y. Liu, S. Liu, S. Liu, W. Liu, X.-D. Liu, X. Liu, X.-H. Liu, X. Liu, X. Liu, X. Liu, Y. Liu, Y. Liu, Z. Liu, Z. Liuzzi, J.P. Lizard, G. Ljujic, M. Lodhi, I.J. Logue, S.E. Lokeshwar, B.L. Long, Y.C. Lonial, S. Loos, B. López-Otín, C. López-Vicario, C. Lorente, M. Lorenzi, P.L. Lõrincz, P. Los, M. Lotze, M.T. Lovat, P.E. Lu, B. Lu, B. Lu, J. Lu, Q. Lu, S.-M. Lu, S. Lu, Y. Luciano, F. Luckhart, S. Lucocq, J.M. Ludovico, P. Lugea, A. Lukacs, N.W. Lum, J.J. Lund, A.H. Luo, H. Luo, J. Luo, S. Luparello, C. Lyons, T. Ma, J. Ma, Y. Ma, Y. Ma, Z. Machado, J. Machado-Santelli, G.M. Macian, F. MacIntosh, G.C. MacKeigan, J.P. Macleod, K.F. MacMicking, J.D. MacMillan-Crow, L.A. Madeo, F. Madesh, M. Madrigal-Matute, J. Maeda, A. Maeda, T. Maegawa, G. Maellaro, E. Maes, H. Magariños, M. Maiese, K. Maiti, T.K. Maiuri, L. Maiuri, M.C. Maki, C.G. Malli, R. Malorni, W. Maloyan, A. Mami-Chouaib, F. Man, N. Mancias, J.D. Mandelkow, E.-M. Mandell, M.A. Manfredi, A.A. Manié, S.N. Manzoni, C. Mao, K. Mao, Z. Mao, Z.-W. Marambaud, P. Marconi, A.M. Marelja, Z. Marfe, G. Margeta, M. Margittai, E. Mari, M. Mariani, F.V. Marin, C. Marinelli, S. Mariño, G. Markovic, I. Marquez, R. Martelli, A.M. Martens, S. Martin, K.R. Martin, S.J. Martin, S. Martin-Acebes, M.A. Martín-Sanz, P. Martinand-Mari, C. Martinet, W. Martinez, J. Martinez-Lopez, N. Martinez-Outschoorn, U. Martínez-Velázquez, M. Martinez-Vicente, M. Martins, W.K. Mashima, H. Mastrianni, J.A. Matarese, G. Matarrese, P. Mateo, R. Matoba, S. Matsumoto, N. Matsushita, T. Matsuura, A. Matsuzawa, T. Mattson, M.P. Matus, S. Maugeri, N. Mauvezin, C. Mayer, A. Maysinger, D. Mazzolini, G.D. McBrayer, M.K. McCall, K. McCormick, C. McInerney, G.M. McIver, S.C. McKenna, S. McMahon, J.J. McNeish, I.A. Mechta-Grigoriou, F. Medema, J.P. Medina, D.L. Megyeri, K. Mehrpour, M. Mehta, J.L. Mei, Y. Meier, U.-C. Meijer, A.J. Meléndez, A. Melino, G. Melino, S. de Melo, E.J.T. Mena, M.A. Meneghini, M.D. Menendez, J.A. Menezes, R. Meng, L. Meng, L.-H. Meng, S. Menghini, R. Menko, A.S. Menna-Barreto, R.F.S. Menon, M.B. Meraz-Ríos, M.A. Merla, G. Merlini, L. Merlot, A.M. Meryk, A. Meschini, S. Meyer, J.N. Mi, M.-T. Miao, C.-Y. Micale, L. Michaeli, S. Michiels, C. Migliaccio, A.R. Mihailidou, A.S. Mijaljica, D. Mikoshiba, K. Milan, E. Miller-Fleming, L. Mills, G.B. Mills, I.G. Minakaki, G. Minassian, B.A. Ming, X.-F. Minibayeva, F. Minina, E.A. Mintern, J.D. Minucci, S. Miranda-Vizuete, A. Mitchell, C.H. Miyamoto, S. Miyazawa, K. Mizushima, N. Mnich, K. Mograbi, B. Mohseni, S. Moita, L.F. Molinari, M. Molinari, M. Møller, A.B. Mollereau, B. Mollinedo, F. Mongillo, M. Monick, M.M. Montagnaro, S. Montell, C. Moore, D.J. Moore, M.N. Mora-Rodriguez, R. Moreira, P.I. Morel, E. Morelli, M.B. Moreno, S. Morgan, M.J. Moris, A. Moriyasu, Y. Morrison, J.L. Morrison, L.A. Morselli, E. Moscat, J. Moseley, P.L. Mostowy, S. Motori, E. Mottet, D. Mottram, J.C. Moussa, C.E.-H. Mpakou, V.E. Mukhtar, H. Levy, J.M.M. Muller, S. Muñoz-Moreno, R. Muñoz-Pinedo, C. Münz, C. Murphy, M.E. Murray, J.T. Murthy, A. Mysorekar, I.U. Nabi, I.R. Nabissi, M. Nader, G.A. Nagahara, Y. Nagai, Y. Nagata, K. Nagelkerke, A. Nagy, P. Naidu, S.R. Nair, S. Nakano, H. Nakatogawa, H. Nanjundan, M. Napolitano, G. Naqvi, N.I. Nardacci, R. Narendra, D.P. Narita, M. Nascimbeni, A.C. Natarajan, R. Navegantes, L.C. Nawrocki, S.T. Nazarko, T.Y. Nazarko, V.Y. Neill, T. Neri, L.M. Netea, M.G. Netea-Maier, R.T. Neves, B.M. Ney, P.A. Nezis, I.P. Nguyen, H.T.T. Nguyen, H.P. Nicot, A.-S. Nilsen, H. Nilsson, P. Nishimura, M. Nishino, I. Niso-Santano, M. Niu, H. Nixon, R.A. Njar, V.C.O. Noda, T. Noegel, A.A. Nolte, E.M. Norberg, E. Norga, K.K. Noureini, S.K. Notomi, S. Notterpek, L. Nowikovsky, K. Nukina, N. Nürnberger, T. O'donnell, V.B. O'donovan, T. O'dwyer, P.J. Oehme, I. Oeste, C.L. Ogawa, M. Ogretmen, B. Ogura, Y. Oh, Y.J. Ohmuraya, M. Ohshima, T. Ojha, R. Okamoto, K. Okazaki, T. Oliver, F.J. Ollinger, K. Olsson, S. Orban, D.P. Ordonez, P. Orhon, I. Orosz, L. O'rourke, E.J. Orozco, H. Ortega, A.L. Ortona, E. Osellame, L.D. Oshima, J. Oshima, S. Osiewacz, H.D. Otomo, T. Otsu, K. Ou, J.-H.J. Outeiro, T.F. Ouyang, D.-Y. Ouyang, H. Overholtzer, M. Ozbun, M.A. Ozdinler, P.H. Ozpolat, B. Pacelli, C. Paganetti, P. Page, G. Pages, G. Pagnini, U. Pajak, B. Pak, S.C. Pakos-Zebrucka, K. Pakpour, N. Palková, Z. Palladino, F. Pallauf, K. Pallet, N. Palmieri, M. Paludan, S.R. Palumbo, C. Palumbo, S. Pampliega, O. Pan, H. Pan, W. Panaretakis, T. Pandey, A. Pantazopoulou, A. Papackova, Z. Papademetrio, D.L. Papassideri, I. Papini, A. Parajuli, N. Pardo, J. Parekh, V.V. Parenti, G. Park, J.-I. Park, J. Park, O.K. Parker, R. Parlato, R. Parys, J.B. Parzych, K.R. Pasquet, J.-M. Pasquier, B. Pasumarthi, K.B.S. Patterson, C. Pattingre, S. Pattison, S. Pause, A. Pavenstädt, H. Pavone, F. Pedrozo, Z. Peña, F.J. Peñalva, M.A. Pende, M. Peng, J. Penna, F. Penninger, J.M. Pensalfini, A. Pepe, S. Pereira, G.J.S. Pereira, P.C. de la Cruz, V.P. Pérez-Pérez, M.E. Pérez-Rodríguez, D. Pérez-Sala, D. Perier, C. Perl, A. Perlmutter, D.H. Perrotta, I. Pervaiz, S. Pesonen, M. Pessin, J.E. Peters, G.J. Petersen, M. Petrache, I. Petrof, B.J. Petrovski, G. Phang, J.M. Piacentini, M. Pierdominici, M. Pierre, P. Pierrefite-Carle, V. Pietrocola, F. Pimentel-Muiños, F.X. Pinar, M. Pineda, B. Pinkas-Kramarski, R. Pinti, M. Pinton, P. Piperdi, B. Piret, J.M. Platanias, L.C. Platta, H.W. Plowey, E.D. Pöggeler, S. Poirot, M. Polčic, P. Poletti, A. Poon, A.H. Popelka, H. Popova, B. Poprawa, I. Poulose, S.M. Poulton, J. Powers, S.K. Powers, T. Pozuelo-Rubio, M. Prak, K. Prange, R. Prescott, M. Priault, M. Prince, S. Proia, R.L. Proikas-Cezanne, T. Prokisch, H. Promponas, V.J. Przyklenk, K. Puertollano, R. Pugazhenthi, S. Puglielli, L. Pujol, A. Puyal, J. Pyeon, D. Qi, X. Qian, W.-B. Qin, Z.-H. Qiu, Y. Qu, Z. Quadrilatero, J. Quinn, F. Raben, N. Rabinowich, H. Radogna, F. Ragusa, M.J. Rahmani, M. Raina, K. Ramanadham, S. Ramesh, R. Rami, A. Randall-Demllo, S. Randow, F. Rao, H. Rao, V.A. Rasmussen, B.B. Rasse, T.M. Ratovitski, E.A. Rautou, P.-E. Ray, S.K. Razani, B. Reed, B.H. Reggiori, F. Rehm, M. Reichert, A.S. Rein, T. Reiner, D.J. Reits, E. Ren, J. Ren, X. Renna, M. Reusch, J.E.B. Revuelta, J.L. Reyes, L. Rezaie, A.R. Richards, R.I. Richardson, R. Richetta, C. Riehle, M.A. Rihn, B.H. Rikihisa, Y. Riley, B.E. Rimbach, G. Rippo, M.R. Ritis, K. Rizzi, F. Rizzo, E. Roach, P.J. Robbins, J. Roberge, M. Roca, G. Roccheri, M.C. Rocha, S. Rodrigues, C.M.P. Rodríguez, C.I. de Cordoba, S.R. Rodriguez-Muela, N. Roelofs, J. Rogov, V.V. Rohn, T.T. Rohrer, B. Romanelli, D. Romani, L. Romano, P.S. Roncero, M.I.G. Rosa, J.L. Rosello, A. Rosen, K.V. Rosenstiel, P. Rost-Roszkowska, M. Roth, K.A. Roué, G. Rouis, M. Rouschop, K.M. Ruan, D.T. Ruano, D. Rubinsztein, D.C. Rucker, E.B., III Rudich, A. Rudolf, E. Rudolf, R. Ruegg, M.A. Ruiz-Roldan, C. Ruparelia, A.A. Rusmini, P. Russ, D.W. Russo, G.L. Russo, G. Russo, R. Rusten, T.E. Ryabovol, V. Ryan, K.M. Ryter, S.W. Sabatini, D.M. Sacher, M. Sachse, C. Sack, M.N. Sadoshima, J. Saftig, P. Sagi-Eisenberg, R. Sahni, S. Saikumar, P. Saito, T. Saitoh, T. Sakakura, K. Sakoh-Nakatogawa, M. Sakuraba, Y. Salazar-Roa, M. Salomoni, P. Saluja, A.K. Salvaterra, P.M. Salvioli, R. Samali, A. Sanchez, A.M.J. Sánchez-Alcázar, J.A. Sanchez-Prieto, R. Sandri, M. Sanjuan, M.A. Santaguida, S. Santambrogio, L. Santoni, G. Dos Santos, C.N. Saran, S. Sardiello, M. Sargent, G. Sarkar, P. Sarkar, S. Sarrias, M.R. Sarwal, M.M. Sasakawa, C. Sasaki, M. Sass, M. Sato, K. Sato, M. Satriano, J. Savaraj, N. Saveljeva, S. Schaefer, L. Schaible, U.E. Scharl, M. Schatzl, H.M. Schekman, R. Scheper, W. Schiavi, A. Schipper, H.M. Schmeisser, H. Schmidt, J. Schmitz, I. Schneider, B.E. Schneider, E.M. Schneider, J.L. Schon, E.A. Schönenberger, M.J. Schönthal, A.H. Schorderet, D.F. Schröder, B. Schuck, S. Schulze, R.J. Schwarten, M. Schwarz, T.L. Sciarretta, S. Scotto, K. Scovassi, A.I. Screaton, R.A. Screen, M. Seca, H. Sedej, S. Segatori, L. Segev, N. Seglen, P.O. Seguí-Simarro, J.M. Segura-Aguilar, J. Seiliez, I. Seki, E. Sell, C. Semenkovich, C.F. Semenza, G.L. Sen, U. Serra, A.L. Serrano-Puebla, A. Sesaki, H. Setoguchi, T. Settembre, C. Shacka, J.J. Shajahan-Haq, A.N. Shapiro, I.M. Sharma, S. She, H. Shen, C.-K.J. Shen, C.-C. Shen, H.-M. Shen, S. Shen, W. Sheng, R. Sheng, X. Sheng, Z.-H. Shepherd, T.G. Shi, J. Shi, Q. Shi, Q. Shi, Y. Shibutani, S. Shibuya, K. Shidoji, Y. Shieh, J.-J. Shih, C.-M. Shimada, Y. Shimizu, S. Shin, D.W. Shinohara, M.L. Shintani, M. Shintani, T. Shioi, T. Shirabe, K. Shiri-Sverdlov, R. Shirihai, O. Shore, G.C. Shu, C.-W. Shukla, D. Sibirny, A.A. Sica, V. Sigurdson, C.J. Sigurdsson, E.M. Sijwali, P.S. Sikorska, B. Silveira, W.A. Silvente-Poirot, S. Silverman, G.A. Simak, J. Simmet, T. Simon, A.K. Simon, H.-U. Simone, C. Simons, M. Simonsen, A. Singh, R. Singh, S.V. Singh, S.K. Sinha, D. Sinha, S. Sinicrope, F.A. Sirko, A. Sirohi, K. Sishi, B.J.N. Sittler, A. Siu, P.M. Sivridis, E. Skwarska, A. Slack, R. Slaninová, I. Slavov, N. Smaili, S.S. Smalley, K.S.M. Smith, D.R. Soenen, S.J. Soleimanpour, S.A. Solhaug, A. Somasundaram, K. Son, J.H. Sonawane, A. Song, C. Song, F. Song, H.K. Song, J.-X. Song, W. Soo, K.Y. Sood, A.K. Soong, T.W. Soontornniyomkij, V. Sorice, M. Sotgia, F. Soto-Pantoja, D.R. Sotthibundhu, A. Sousa, M.J. Spaink, H.P. Span, P.N. Spang, A. Sparks, J.D. Speck, P.G. Spector, S.A. Spies, C.D. Springer, W. Clair, D.S. Stacchiotti, A. Staels, B. Stang, M.T. Starczynowski, D.T. Starokadomskyy, P. Steegborn, C. Steele, J.W. Stefanis, L. Steffan, J. Stellrecht, C.M. Stenmark, H. Stepkowski, T.M. Stern, S.T. Stevens, C. Stockwell, B.R. Stoka, V. Storchova, Z. Stork, B. Stratoulias, V. Stravopodis, D.J. Strnad, P. Strohecker, A.M. Ström, A.-L. Stromhaug, P. Stulik, J. Su, Y.-X. Su, Z. Subauste, C.S. Subramaniam, S. Sue, C.M. Suh, S.W. Sui, X. Sukseree, S. Sulzer, D. Sun, F.-L. Sun, J. Sun, J. Sun, S.-Y. Sun, Y. Sun, Y. Sun, Y. Sundaramoorthy, V. Sung, J. Suzuki, H. Suzuki, K. Suzuki, N. Suzuki, T. Suzuki, Y.J. Swanson, M.S. Swanton, C. Swärd, K. Swarup, G. Sweeney, S.T. Sylvester, P.W. Szatmari, Z. Szegezdi, E. Szlosarek, P.W. Taegtmeyer, H. Tafani, M. Taillebourg, E. Tait, S.W.G. Takacs-Vellai, K. Takahashi, Y. Takáts, S. Takemura, G. Takigawa, N. Talbot, N.J. Tamagno, E. Tamburini, J. Tan, C.-P. Tan, L. Tan, M.L. Tan, M. Tan, Y.-J. Tanaka, K. Tanaka, M. Tang, D. Tang, D. Tang, G. Tanida, I. Tanji, K. Tannous, B.A. Tapia, J.A. Tasset-Cuevas, I. Tatar, M. Tavassoly, I. Tavernarakis, N. Taylor, A. Taylor, G.S. Taylor, G.A. Taylor, J.P. Taylor, M.J. Tchetina, E.V. Tee, A.R. Teixeira-Clerc, F. Telang, S. Tencomnao, T. Teng, B.-B. Teng, R.-J. Terro, F. Tettamanti, G. Theiss, A.L. Theron, A.E. Thomas, K.J. Thomé, M.P. Thomes, P.G. Thorburn, A. Thorner, J. Thum, T. Thumm, M. Thurston, T.L.M. Tian, L. Till, A. Ting, J.P.-Y. Ting, J.P.Y. Titorenko, V.I. Toker, L. Toldo, S. Tooze, S.A. Topisirovic, I. Torgersen, M.L. Torosantucci, L. Torriglia, A. Torrisi, M.R. Tournier, C. Towns, R. Trajkovic, V. Travassos, L.H. Triola, G. Tripathi, D.N. Trisciuoglio, D. Troncoso, R. Trougakos, I.P. Truttmann, A.C. Tsai, K.-J. Tschan, M.P. Tseng, Y.-H. Tsukuba, T. Tsung, A. Tsvetkov, A.S. Tu, S. Tuan, H.-Y. Tucci, M. Tumbarello, D.A. Turk, B. Turk, V. Turner, R.F.B. Tveita, A.A. Tyagi, S.C. Ubukata, M. Uchiyama, Y. Udelnow, A. Ueno, T. Umekawa, M. Umemiya-Shirafuji, R. Underwood, B.R. Ungermann, C. Ureshino, R.P. Ushioda, R. Uversky, V.N. Uzcátegui, N.L. Vaccari, T. Vaccaro, M.I. Váchová, L. Vakifahmetoglu-Norberg, H. Valdor, R. Valente, E.M. Vallette, F. Valverde, A.M. Van den Berghe, G. Van Den Bosch, L. van den Brink, G.R. van der Goot, F.G. van der Klei, I.J. van der Laan, L.J.W. van Doorn, W.G. van Egmond, M. van Golen, K.L. Van Kaer, L. Campagne, M.L. Vandenabeele, P. Vandenberghe, W. Vanhorebeek, I. Varela-Nieto, I. Vasconcelos, M.H. Vasko, R. Vavvas, D.G. Vega-Naredo, I. Velasco, G. Velentzas, A.D. Velentzas, P.D. Vellai, T. Vellenga, E. Vendelbo, M.H. Venkatachalam, K. Ventura, N. Ventura, S. Veras, P.S.T. Verdier, M. Vertessy, B.G. Viale, A. Vidal, M. Vieira, H.L.A. Vierstra, R.D. Vigneswaran, N. Vij, N. Vila, M. Villar, M. Villar, V.H. Villarroya, J. Vindis, C. Viola, G. Viscomi, M.T. Vitale, G. Vogl, D.T. Voitsekhovskaja, O.V. von Haefen, C. von Schwarzenberg, K. Voth, D.E. Vouret-Craviari, V. Vuori, K. Vyas, J.M. Waeber, C. Walker, C.L. Walker, M.J. Walter, J. Wan, L. Wan, X. Wang, B. Wang, C. Wang, C.-Y. Wang, C. Wang, C. Wang, C. Wang, D. Wang, F. Wang, F. Wang, G. Wang, H.-J. Wang, H. Wang, H.-G. Wang, H. Wang, H.-D. Wang, J. Wang, J. Wang, M. Wang, M.-Q. Wang, P.-Y. Wang, P. Wang, R.C. Wang, S. Wang, T.-F. Wang, X. Wang, X.-J. Wang, X.-W. Wang, X. Wang, X. Wang, Y. Wang, Y. Wang, Y. Wang, Y.-J. Wang, Y. Wang, Y. Wang, Y.T. Wang, Y. Wang, Z.-N. Wappner, P. Ward, C. Ward, D.M.V. Warnes, G. Watada, H. Watanabe, Y. Watase, K. Weaver, T.E. Weekes, C.D. Wei, J. Weide, T. Weihl, C.C. Weindl, G. Weis, S.N. Wen, L. Wen, X. Wen, Y. Westermann, B. Weyand, C.M. White, A.R. White, E. Whitton, J.L. Whitworth, A.J. Wiels, J. Wild, F. Wildenberg, M.E. Wileman, T. Wilkinson, D.S. Wilkinson, S. Willbold, D. Williams, C. Williams, K. Williamson, P.R. Winklhofer, K.F. Witkin, S.S. Wohlgemuth, S.E. Wollert, T. Wolvetang, E.J. Wong, E. Wong, G.W. Wong, R.W. Wong, V.K.W. Woodcock, E.A. Wright, K.L. Wu, C. Wu, D. Wu, G.S. Wu, J. Wu, J. Wu, M. Wu, M. Wu, S. Wu, W.K.K. Wu, Y. Wu, Z. Xavier, C.P.R. Xavier, R.J. Xia, G.-X. Xia, T. Xia, W. Xia, Y. Xiao, H. Xiao, J. Xiao, S. Xiao, W. Xie, C.-M. Xie, Z. Xie, Z. Xilouri, M. Xiong, Y. Xu, C. Xu, C. Xu, F. Xu, H. Xu, H. Xu, J. Xu, J. Xu, J. Xu, L. Xu, X. Xu, Y. Xu, Y. Xu, Z.-X. Xu, Z. Xue, Y. Yamada, T. Yamamoto, A. Yamanaka, K. Yamashina, S. Yamashiro, S. Yan, B. Yan, B. Yan, X. Yan, Z. Yanagi, Y. Yang, D.-S. Yang, J.-M. Yang, L. Yang, M. Yang, P.-M. Yang, P. Yang, Q. Yang, W. Yang, W.Y. Yang, X. Yang, Y. Yang, Y. Yang, Z. Yang, Z. Yao, M.-C. Yao, P.J. Yao, X. Yao, Z. Yao, Z. Yasui, L.S. Ye, M. Yedvobnick, B. Yeganeh, B. Yeh, E.S. Yeyati, P.L. Yi, F. Yi, L. Yin, X.-M. Yip, C.K. Yoo, Y.-M. Yoo, Y.H. Yoon, S.-Y. Yoshida, K.-I. Yoshimori, T. Young, K.H. Yu, H. Yu, J.J. Yu, J.-T. Yu, J. Yu, L. Yu, W.H. Yu, X.-F. Yu, Z. Yuan, J. Yuan, Z.-M. Yue, B.Y.J.T. Yue, J. Yue, Z. Zacks, D.N. Zacksenhaus, E. Zaffaroni, N. Zaglia, T. Zakeri, Z. Zecchini, V. Zeng, J. Zeng, M. Zeng, Q. Zervos, A.S. Zhang, D.D. Zhang, F. Zhang, G. Zhang, G.-C. Zhang, H. Zhang, H. Zhang, H. Zhang, J. Zhang, J. Zhang, J. Zhang, J.-P. Zhang, L. Zhang, L. Zhang, L. Zhang, M.-Y. Zhang, X. Zhang, X.D. Zhang, Y. Zhang, Y. Zhang, Y. Zhang, Y. Zhang, Y. Zhao, M. Zhao, W.-L. Zhao, X. Zhao, Y.G. Zhao, Y. Zhao, Y. Zhao, Y.-X. Zhao, Z. Zhao, Z.J. Zheng, D. Zheng, X.-L. Zheng, X. Zhivotovsky, B. Zhong, Q. Zhou, G.-Z. Zhou, G. Zhou, H. Zhou, S.-F. Zhou, X.-J. Zhu, H. Zhu, H. Zhu, W.-G. Zhu, W. Zhu, X.-F. Zhu, Y. Zhuang, S.-M. Zhuang, X. Ziparo, E. Zois, C.E. Zoladek, T. Zong, W.-X. Zorzano, A. Zughaier, S.M.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results